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Abstract
Background: It is perceived that little is known about the epidemiology of HIV infection among people who inject drugs
(PWID) in the Middle East and North Africa (MENA). The primary objective of this study was to assess the status of the HIV
epidemic among PWID in MENA by describing HIV prevalence and incidence. Secondary objectives were to describe the risk
behavior environment and the HIV epidemic potential among PWID, and to estimate the prevalence of injecting drug use in
MENA.
Methods and Findings: This was a systematic review following the PRISMA guidelines and covering 23 MENA countries.
PubMed, Embase, regional and international databases, as well as country-level reports were searched up to December 16,
2013. Primary studies reporting (1) the prevalence/incidence of HIV, other sexually transmitted infections, or hepatitis C virus
(HCV) among PWIDs; or (2) the prevalence of injecting or sexual risk behaviors, or HIV knowledge among PWID; or (3) the
number/proportion of PWID in MENA countries, were eligible for inclusion. The quality, quantity, and geographic coverage
of the data were assessed at country level. Risk of bias in predefined quality domains was described to assess the quality of
available HIV prevalence measures. After multiple level screening, 192 eligible reports were included in the review. There
were 197 HIV prevalence measures on a total of 58,241 PWID extracted from reports, and an additional 226 HIV prevalence
measures extracted from the databases. We estimated that there are 626,000 PWID in MENA (range: 335,000–1,635,000,
prevalence of 0.24 per 100 adults). We found evidence of HIV epidemics among PWID in at least one-third of MENA
countries, most of which are emerging concentrated epidemics and with HIV prevalence overall in the range of 10%–15%.
Some of the epidemics have however already reached considerable levels including some of the highest HIV prevalence
among PWID globally (87.1% in Tripoli, Libya). The relatively high prevalence of sharing needles/syringes (18%–28% in the
last injection), the low levels of condom use (20%–54% ever condom use), the high levels of having sex with sex workers
and of men having sex with men (15%–30% and 2%–10% in the last year, respectively), and of selling sex (5%–29% in the
last year), indicate a high injecting and sexual risk environment. The prevalence of HCV (31%–64%) and of sexually
transmitted infections suggest high levels of risk behavior indicative of the potential for more and larger HIV epidemics.
Conclusions: Our study identified a large volume of HIV-related biological and behavioral data among PWID in the MENA
region. The coverage and quality of the data varied between countries. There is robust evidence for HIV epidemics among
PWID in multiple countries, most of which have emerged within the last decade and continue to grow. The lack of sufficient
evidence in some MENA countries does not preclude the possibility of hidden epidemics among PWID in these settings.
With the HIV epidemic among PWID in overall a relatively early phase, there is a window of opportunity for prevention that
should not be missed through the provision of comprehensive programs, including scale-up of harm reduction services and
expansion of surveillance systems.
Please see later in the article for the Editors’ Summary.
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Introduction
The Middle East and North Africa (MENA) region has been
singled out as the region with little data and where the status of the
HIV/AIDS epidemic remained unknown [1–8]. In 2005, the
region was characterized as ‘‘a real hole in terms of HIV/AIDS
epidemiological data’’ [9]. The MENA region has, however,
witnessed a remarkable growth in HIV research over the last
decade, with several countries developing surveillance systems to
monitor the spread of HIV infection, including among most-at-risk
populations [10].
A large fraction of studies conducted in the region has remained
unpublished in the scientific literature, and only available in the
form of difficult to access country reports. This has meant that
data have not been analyzed or synthesized at either country or
regional level, and no critical assessment of the quality of available
evidence has been conducted. The rationale for this study came
from signs of a growing HIV disease burden in the MENA region,
which highlighted the urgent need for a critical and comprehen-
sive evaluation of the status of the HIV epidemic and of the quality
of evidence among the different population groups to inform HIV
policy and programming in the region; this was the mandate of the
MENA HIV/AIDS Synthesis Project, the largest HIV study in
MENA to date [11].
The present article follows on from a series of studies conducted
as part of the Synthesis Project. These studies include a high-level
overview of HIV epidemiology in MENA [12], a systematic review
of HIV molecular evidence [13], and the first documentation of
the emerging HIV epidemic among men who have sex with men
(MSM) in MENA [14]. The present study is, to our knowledge, the
first systematic review and data synthesis to characterize the status
of the HIV epidemic among people who inject drugs (PWID) in
MENA. The presented regional analysis takes on an additional
importance with the need to capture the volume of bio-behavioral
surveillance data that became available within the last few years in
MENA, and is yet to be analyzed and synthesized within a
country-specific or a regional context [15].
PWID are one of the key populations at high risk of HIV in
MENA, a region with several vulnerability factors for injecting
drug use. For example, 83% of the global supply of heroin is
produced in Afghanistan [16], and over 75% of this is trafficked
through Iran and Pakistan. In 2009, Iran bore the highest fraction
of the global opium and heroin seizures (89% and 33%,
respectively) [16]. Increased availability and purity of heroin at
lower prices in MENA appears to have led to a subsequent rise in
injecting drug use [17]. In 2010, one gram of heroin in
Afghanistan could be purchased for about US$4 compared with
up to US$100 in West and Central Europe, US$200 in the United
States and Northern Europe, and US$370 in Australia [16]. Most
PWID in the region are young adults and marginalized by family
members and society; they are stigmatized and lack access to
comprehensive and confidential HIV prevention and treatment
services [11].
The primary objective of this study was to assess the status of
the HIV epidemic among PWID in MENA by describing HIV
prevalence and incidence. The secondary objective was to
describe the risk behavior environment and the HIV epidemic
potential among PWID by describing (1) their injecting and
sexual risk behavior and knowledge, and (2) prevalence of proxy
biological markers of these behaviors, namely hepatitis C virus
(HCV) and sexually transmitted infections (STIs), respectively.
The study also estimated the proportion and number of PWID in
MENA.
Methods
We followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) (Text S1) [18,19] and
Cochrane Collaboration guidelines [20].
Data Sources and Search Strategy
Our review covered the 23 countries included in the MENA
definitions of the three international organizations leading the
regional HIV response efforts in the region: the Joint United
Nations Programme on HIV/AIDS (UNAIDS), the Eastern
Mediterranean Regional Office of the World Health Organi-
zation (WHO/EMRO), and the World Bank (Figure 1). These
countries share specific similarities, whether historical, socio-
cultural, or linguistic; and are conventionally included together
as part of HIV/AIDS programming for the region.
The following sources of data were searched up to December
16, 2013: (1) Scientific databases (PubMed, Embase, and regional
databases [WHO African Index Medicus [21] and WHO Index
Medicus for the Eastern Mediterranean Region [22]]), with no
publication date or language restrictions. A generic search of
‘‘drug use’’ in MENA was performed in PubMed and Embase
using MeSH/Emtree and text terms. The term ‘‘HIV’’ was not
included to avoid detection bias. (2) The MENA HIV/AIDS
Synthesis Project database of grey and mainly unpublished
literature [11,12]. (3) Abstracts of the International AIDS
Conference 2002–2012 [23], the International AIDS Society
Conference on HIV Pathogenesis and Treatment 2001–2013
[24], and the International Society for Sexually Transmitted
Diseases Research Conferences 2003–2013 [25]. (4) International
and regional databases of HIV prevalence measures including the
US Census Bureau database of HIV/AIDS [26], the WHO/
EMRO HIV testing database [27], and the UNAIDS epidemi-
ological fact sheets database [28].
Details of the search criteria are provided in Text S2.
Reference lists of all relevant papers and review articles were
also searched.
Study Selection
Titles and abstracts of all records identified were screened
independently by two authors (GRM and SR), and consensus on
potential eligibility reached. Full texts of potentially relevant
records were retrieved and assessed for eligibility. Studies satisfying
any of the below criteria were eligible: (1) The proportion of
PWID in the sample was specified, at least half were PWID, and
data on any of the following outcomes were included: Prevalence
or incidence of HIV; prevalence of injecting or sexual risk
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behaviors, or knowledge; prevalence or incidence of HCV; and
prevalence or incidence of other STIs. HCV is transmitted
primarily through percutaneous exposures and can be used as a
proxy of the risk of parenteral exposure to HIV. Among PWID, a
threshold HCV prevalence of about 30% implies sufficient risk
behavior to sustain HIV transmission [29,30]. Similarly, the
prevalence of STIs is a useful marker of sexual risk behavior and
potential for HIV sexual acquisition. (2) Data on population-based
prevalence of injecting drug use or PWID population size
estimates were reported.
Only studies with primary data were included. The only
exception was in relation to national estimates of the number and
proportion of PWID in a number of MENA countries where the
only available source of data was from two global reviews [4,31]
that published data compiled through the Reference Group to the
UN on HIV and Injecting Drug Use [32].
We used the term report to refer to the documents (papers,
conference abstracts, or public health reports) presenting findings
of a study [20]. Reports could contribute to more than one
outcome. Findings duplicated in more than one report were
included only once (using the more detailed report). Outcomes in
more than one population/setting within a report were included
separately.
Data Extraction
Data were extracted by one of the authors (GRM) using a
pre-piloted data extraction form and entered into a comput-
erized database. Double extraction on about 45% of records
was confirmed by another author (LA-R). The few discrepan-
cies were settled by consensus or by contacting authors. Data
from articles in English, French, and Arabic were extracted
from the full -texts. Data from records in Farsi (n= 6) were
extracted from the English abstract. There were no records in
other languages.
As supporting information, we also analyzed data extracted
from countries’ reporting on the HIV epidemic to WHO/EMRO
in the format of aggregate HIV case notifications.
Scope and Quality of the Evidence
We appraised the status of the evidence on our main outcome,
HIV prevalence, at country level by examining the following
criteria that take into consideration the quantity, quality, and
geographical coverage of available data: (1) the number of HIV
prevalence measures and the total sample size they cover, (2) the
number of geographic settings with HIV prevalence measures, (3)
the number of multi-city studies and the maximum number
of cities per study, (4) the number of rounds of integrated
Figure 1. Map of the Middle East and North Africa region. The defintion adopted in the review includes the following 23 countires:
Afghanistan, Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, OPT, Pakistan, Qatar, Saudi Arabia, Somalia,
Sudan (including the newly established Republic of South Sudan), Syria, Tunisia, United Arab Emirates (UAE), and Yemen.
doi:10.1371/journal.pmed.1001663.g001
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bio-behavioral surveillance surveys (IBBSS), and (5) the quality
and precision of individual HIV prevalence measures.
The quality of individual HIV prevalence measures was assessed
by describing the risk of bias (ROB). Since the number of
prevalence measures among female PWID was very small and
often based on small sub-samples, the quality appraisal was
restricted to HIV prevalence among predominantly male PWID.
Based on the Cochrane approach for assessing ROB [20], we
classified each HIV prevalence measure as having a low, high, or
unclear ROB for three quality domains: the sampling methodol-
ogy, the type of HIV ascertainment, and the response rate. Low
ROB was considered if (1) sampling was probability-based or
preceded by ethnographic mapping, (2) HIV was ascertained with
a biological assay, and (3) the response rate was over 80%; or over
80% of the target sample size was reached. HIV prevalence
measures extracted from international and regional databases
were considered of unknown quality since original reports were
not available for assessing their ROB.
A minimum sample size of 100 was considered to produce
estimates with good precision. For a median HIV prevalence
among PWID in MENA of 8% (see Results), this implies a 95% CI
of 4%–15%.
The quality of the evidence in each country was assessed by
combining the above factors as described in Text S3. For example,
quality was considered better if at least one round of IBBSS was
conducted, since these surveys use standard methodology includ-
ing state of the art sampling techniques of hard-to-reach
populations (such as respondent-driven sampling). Countries were
categorized as having: (1) No evidence: virtually no data. (2) Poor
evidence: The majority of HIV biological measures were of poor
quality. (3) Limited evidence: The number of HIV biological
measures was small, but of reasonable quality. (4) Good evidence:
The number of HIV biological measures was small, but with good
quality and informative data. However, the overall volume of data
was not sufficient to be conclusive of the status and scale of the
epidemic at the national level. (5) Conclusive evidence: There was
a sufficient volume of robust evidence to support the conclusion.
Analysis
The low-bound, middle, and high-bound national estimates of
the number and prevalence of injecting drug use in MENA
countries were extracted from reports. The pooled number and
prevalence of PWID for the MENA region were estimated
separately using the extracted country-level estimates. The lower
(and upper) bound of our pooled regional estimate of the number
of PWID in MENA was calculated by adding the lowest (and
highest) reported number of PWID in all MENA countries. The
middle figure for the number of PWID in MENA is the sum of the
middle estimates in each of the MENA countries. When more
than one such estimate was available per country, we used the
median of the estimates. The pooled numbers of PWID were
rounded up to the next thousand.
Middle estimates of the extracted prevalence of PWID were
weighted by adult population size to derive the pooled prevalence
of injecting drug use in MENA. When more than one such
estimate was available per country, we used the median of the
estimates. Adult population size was extracted from the United
Nations World Population Database [33]. Sub-national estimates
of the number and prevalence of injecting drug use were extracted
from reports and described separately.
We calculated 95% CI for HIV and HCV prevalence for all
reports with available information. The HIV biological data (HIV
prevalence from reports and from databases, HIV incidence, and
notified HIV cases) were synthesized at country level to assess the
status of the HIV epidemic among PWID. Recent WHO/
UNAIDS guidelines for classifying HIV epidemics [34,35], which
do not recommend use of rigid thresholds [34,36], were adapted to
classify the HIV epidemic level in PWID as: (1) Low-level HIV
epidemic: HIV has not reached significant levels among PWID. (2)
Concentrated HIV epidemic: HIV has reached significant levels
and taken root among PWID through transmission chains
between members of this population. Concentrated epidemics
can be either emerging (HIV has started its initial growth and
continues in a trend of increasing HIV prevalence); or established
(the epidemic has reached its peak and HIV prevalence is
stabilizing towards, or already is at, its endemic level). (3) ‘‘At least
outbreak-type’’: Insufficient evidence to support a concentrated
epidemic among PWID, but some evidence, usually of lower
quality, suggesting that significant HIV transmission has occurred,
or is occurring, among at least some PWID groups.
The terms ‘‘national’’ or ‘‘at least localized’’ were assigned to
concentrated epidemics to reflect the geographical spread of the
epidemic within a given country.
Results
Results of Search Strategy
The study selection process is shown in Figure 2. A total of
6,207 citations were retrieved from PubMed, Embase, and the
regional databases. After full-text screening and including reports
from the other sources, 192 reports were eligible: 121 from
PubMed and Embase, 41 from the MENA HIV/AIDS Synthesis
Project, 13 from bibliographies of relevant reports and review
articles, 13 from the search of scientific conferences, and four from
the regional databases. In addition, 226 HIV point-prevalence
measures were extracted from the databases of biological markers
(Figure 2).
There were 423 HIV prevalence measures, 197 of which were
extracted from the eligible reports and 226 from the databases of
HIV prevalence; three HIV incidence measures; 93 HCV
prevalence measures; four HCV incidence measures; 38 STI
prevalence measures; and 993 behavioral and knowledge mea-
sures. There were also 130 and 96 measures on the number and
proportion of PWID, respectively (Figure 2).
Scope and Quality of the Evidence
The number and quality of HIV prevalence measures varied by
country. The largest volume of data was from Pakistan (101 HIV
prevalence measures on a total of 24,445 PWID), Iran (99 HIV
prevalence measures on a total of 22,181 PWID), and Egypt (39
HIV prevalence measures on a total of 4,480 PWID) (Table 1). A
smaller number of HIV prevalence measures but covering a
relatively large number of PWID were conducted in Afghanistan
(3,277 PWID), Tunisia (1,522 PWID), and Morocco (880 PWID).
Multi-city studies have been conducted in several countries
including Pakistan, where up to 16 cities were included in one
study [37]. IBBSS have been conducted in Afghanistan [38,39],
Egypt [40–42], Iran [43,44], Jordan [45], Lebanon [46], Libya
[47], Morocco [48], Occupied Palestinian Territories (OPT) [49],
Pakistan [37,50–52], and Tunisia (Table 1) [53,54]. Pakistan has
the most repeated rounds of IBBSS with four rounds conducted
between 2005 and 2011 [37,50–52].
Of 190 HIV prevalence measures extracted from eligible
reports and among predominantly male PWID, 98%, 53%, and
34% had low ROB in terms of HIV ascertainment, sampling
methodology, and response rate, respectively. Over 60% of the
190 HIV prevalence measures had low ROB in at least two quality
domains and 84% had good precision (Tables S1 and S2).
HIV among People Who Inject Drugs in MENA
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Figure 2. PRISMA flow chart of study selection in the systematic search.
doi:10.1371/journal.pmed.1001663.g002
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On the basis of the quality of the evidence assessment, the
evidence was determined to be ‘‘conclusive’’ in Iran and Pakistan;
‘‘good’’ in Afghanistan, Egypt, Jordan, Lebanon, Libya, Morocco,
OPT, and Tunisia; ‘‘limited’’ in Bahrain and Syria; and ‘‘poor’’ in
Djibouti, Iraq, Kuwait, Oman, Saudi Arabia, Sudan, and Yemen.
There was ‘‘no evidence’’ in Algeria, Qatar, Somalia, and the
United Arab Emirates. A narrative justification for the classifica-
tion of the scope and quality of evidence is in Text S3.
Although a formal quality assessment was not made for the
secondary outcomes in terms of injecting and sexual risk behavior
and knowledge, the majority of these data were extracted from the
IBBSS studies using standard survey methodology and large
samples. Details of these studies (with information on sample size,
population characteristics, and/or sampling technique) can be
found in the tables summarizing the prevalence of HIV and HCV
among PWID (Tables 3 and 6).
Prevalence of Injecting Drug Use
Table 2 describes national estimates of the number and
prevalence of PWID. These national estimates were extracted
from included reports where they were derived using different
methodologies including indirect methods (such as capture-
recapture and multiplier methods), population-based surveys,
registered number of PWID, and rapid assessments. In two of
the sources of data in Table 2 [4,31], some of the country
estimates are the collation of several such country-specific
estimates using methods described in the original reports [4,31].
Based on available data, the number of PWID in MENA ranges
between a low bound of 335,000 and a high bound of 1,635,000,
with a middle estimate of 626,000 PWID. Iran, Pakistan, and
Egypt have the largest number, with a median of about 185,000,
117,000, and 89,000 PWID, respectively. The weighted mean
prevalence of injecting drug use in MENA is 0.24 per 100 adults.
It is lowest in Somalia (0.03%) and highest in Iran (0.43%)
(Table 2).
Studies of sub-national populations showed geographical
heterogeneity (Table S3). For example, in Iran, the prevalence
of injecting drug use varied between 0.0% in rural Babol province
[55] to 1.0% in Tehran [56]; and in Pakistan it ranged from
0.02% in Rawalpindi to 0.87% and 1.07% in Sargodha and
Faisalabad, respectively [57].
Data on the prevalence of female PWID in MENA were scarce.
Overall, the mean proportion of females among PWID in included
studies was 2.3% (range: 0%–35%). In two studies in Oman and
Syria, 25%–58% [58] and 48% [59] of PWID, respectively,
reported knowing at least one female PWID.
HIV Prevalence, Incidence, and Mode of Transmission
HIV prevalence measures from reports and databases are
summarized in Tables 3 and S4, respectively. Considerable
variation in HIV prevalence was seen, with an overall median of
8% (interquartile range [IQR]: 1%–21%) (Table 3). HIV
prevalence among PWID in MENA ranged between 0% in some
prevalence measures in almost every country up to 7% in Cairo,
Egypt in 2010 (n=274) [42]; 18% in Afghanistan in one city near
the Iranian borders, Herat, in 2009 (n=159) [38]; 21% in
Manama, Bahrain, in the early nineties (n=242) [60]; 27% in
Oman among incarcerated PWID (n=33) [58]; 38% in Nador,
northern Morocco, in 2008 (n=233) [61]; 52% in the third largest
metropolis in Pakistan, Faisalabad, in 2011 (n=364) [37]; 72% in
rural Iran in 2004–5 (n=61) [62]; and 87% in Tripoli, Libya in
2010 (n=328) [47] (Table 3). HIV prevalence was consistently low
among PWID in Jordan, Lebanon, OPT, Syria, and Tunisia (0%–
3.1%). Substantial intra-country variability in HIV prevalence was
observed in Afghanistan, Iran, Morocco, and Pakistan (Table 3).
In most countries with high HIV prevalence, recent studies report
increasing HIV prevalence starting around 2003 (Tables 3 and
S4).
Three HIV incidence studies were identified. In Kabul,
Afghanistan, HIV incidence among a sample of 479 PWID in
2008 was 2.2/100 person-years (pyr), despite 72% of study
participants reporting use of harm reduction services [63]. Among
500 PWID in three cities in Pakistan, HIV incidence was 1.7/100
pyr in 2006 [64]. A very high incidence rate (17.2/100 pyr) was
reported in Tehran, Iran, in 2002 among 214 incarcerated PWID
[65].
Analysis of notified HIV cases indicated that in 2011, injecting
drug use contributed 20% (80/409), 23% (50/216), 38% (6/16),
49% (52/107), and 60% (948/1,588) of all newly notified cases in
this year in Egypt, Pakistan, Bahrain, Afghanistan, and Iran,
respectively. A smaller contribution was reported in the remaining
countries (Table 4).
HIV Epidemic States
The evidence was sufficient to characterize the HIV epidemic
state in 13 countries, summarized in Table 5. Details on how the
conclusions were reached are in Text S3.
Concentrated HIV epidemics. Concentrated HIV epidem-
ics among PWID were observed in Iran, Pakistan, Afghanistan,
Egypt, Morocco, and Libya (Table 5). Iran is the only country with
conclusive evidence for an established concentrated epidemic at
the national level. The first HIV outbreaks among PWID in Iran
were reported around 1996. HIV prevalence then increased
considerably in the early 2000s, reaching a peak by the mid-2000s
(Figure 3A). HIV prevalence in the 2006 and 2010 multi-city
IBBSS was stable at 15% (n=2,853 and n=2,479, respectively)
(Figure 4C) [43,44]. The evidence suggests that the HIV epidemic
among PWID in Iran is now established at concentrated levels of
about 15%.
Emerging concentrated epidemics were seen in Pakistan,
Afghanistan, Egypt, and Morocco (Table 5). For example, in
Pakistan, after almost two decades of very low HIV prevalence
among PWID, a trend of increasing prevalence was observed after
2003 (Figure 3B). This trend is national and ongoing, reaching
over 40% in recent studies and with no evidence yet of
stabilization (Figure 3B). This trend also manifests itself in the
multi-province IBBSS where HIV prevalence among PWID has
steadily increased from 10.8% in 2005 (n=2,431) [52], to 15.8%
in 2006 (n=4,039) [51], 20.8% in 2008 (n=2,969) [50], and
25.2% in 2011 (n=4,593) [37] (Figure 4A). In view of the high
HIV prevalence, the emerging HIV epidemic in Pakistan is
considered advanced. Another example is Egypt where HIV
prevalence was also very low for about two decades (Tables 3 and
S4), including the first round of IBBSS in 2006 [40,41], but
increased to 6%–7% in both cities surveyed in the most recent
IBBSS in 2010 (n=284 and n=274) (Figure 4B) [42]. Consistent-
ly, 19.6% of the 409 newly notified HIV cases in 2010 in Egypt
were due to injecting drug use, compared with only 1.6% of the
total notified cases up to 2008 (Table 4). In Afghanistan (Figure 4E)
and Morocco, the HIV epidemic among PWID appears to be
emerging in at least parts of the country, with notably high HIV
prevalence in some settings, but still low HIV prevalence in others
(Table 3).
The HIV epidemic in Libya is also concentrated, but the trend
is unclear. Libya has the highest reported prevalence of HIV
among PWID in MENA (87.2%, 95% CI 83.1%–90.6% in the
IBBSS in Tripoli [47]). Earlier data, although of unclear quality,
also indicate prevalence of up to 59% in 2001 among PWID in
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Tripoli (Table S4). This indicates a concentrated HIV epidemic
among PWID in at least part of Libya. Although the epidemic in
Tripoli is most likely to be established, the level of evidence overall
is insufficient to characterize whether the national epidemic is
emerging, with few outbreaks in the past, or is established with
endemic HIV transmission among PWID.
‘‘At least outbreak-type’’ HIV epidemics. In Bahrain and
Oman, data show that there are, or have been, at least some
pockets of HIV infection among PWID, with reported prevalence
up to 21.1% (Bahrain, n=242) [60] and 27% (Oman, n=33) [58].
However, most available data are from studies with unknown
methodology or high ROB; therefore, the quality of evidence is
insufficient to indicate whether there is a concentrated epidemic in
these two countries, even if localized.
Low-level HIV epidemics. The HIV epidemic among
PWID is low-level in Jordan, Lebanon, Tunisia, OPT, and Syria
(Table 5). In these countries (except Syria), at least one round of
IBBSS has been conducted, in addition to other data; all indicate
limited HIV spread among PWID (Figure 4D; Tables 3 and S4).
The contribution of injecting drug use to the total notified cases
also remains minimal in these countries, further confirming a low-
level epidemic (Table 4).
Injecting Risk Behavior
Table S5 summarizes injecting risk behavior measures
among PWID in MENA. The key risk behavior that exposes
PWID to HIV infection is the use of non-sterile injecting
equipment. Available data indicate that the lifetime prevalence
of sharing needles/syringes among PWID in MENA was as
high as 71% [45], 79% [66], 85% [47], 95% [67], and 97%
[58] in Jordan, Pakistan, Libya, Iran, and Oman, respectively.
The median prevalence of sharing in the last injection was
23% (IQR: 18%–28%). In Pakistan, most injecting occurs in
groups and in public places, and reported use of ‘‘street
doctors’’ or professional injectors was common, which is
associated with high reuse of injecting equipment (Table S5)
[50].
In MENA, PWID inject drugs at median of 2.2 injections per
day, with reported rates of 3.3 [68] and 5.7 [69] injections per day
among some PWID in Iran and Afghanistan, respectively. The
median age at first injection was 26 years (IQR: 24–28 years), and
the median duration of injecting drugs was 4.6 years (IQR: 3.8–6.1
years) (Table S5).
Sexual Risk Behavior
The majority of PWID in MENA are sexually active (Table S6).
On average, 52% have been ever married (IQR: 35%–56%),
43%–89% report having sex with a regular female partner, 29%–
60% reported multiple sexual partnerships, and 18%–42% report
sex with non-regular female partners in the last year (Table S6).
Reported levels of condom use varied but generally were on the
low to intermediate range. Overall, 36% of PWID reported ever
using condoms (IQR: 20%–54%) with the lowest prevalence in
Afghanistan and Pakistan (10%–38% [70–76]), and the highest in
Lebanon (88% [77]). Condom use during last sex was reported by
4%–38% of PWID, reaching 66% only in Libya [47]. Only 12%–
25% of PWID reported consistent condom use in the last year
(Table S6).
Mixing with Other High-Risk Populations
Risk behaviors of PWID in MENA overlap considerably
with other high-risk populations, namely MSM and female sex
workers. A median of 18% of male PWID in MENA reported
ever having sex with men (IQR: 11%–27%), and a median of
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7% did so in the last year (IQR: 2%–10%) (Table S6). The
highest rates of same-sex sex have been reported in Pakistan.
Reported condom use during anal sex was overall very low
(Table S6).
PWID in MENA engage in sex work, either through buying
or selling sex. A median of 45% reported ever having sex with a
sex worker (IQR: 31%–64%), and a median of 23% did so in
the last year (IQR: 15%–30%), with generally low levels of
condom use (Table S6). Selling sex in the past year was reported
by 5%–29% of PWID in Egypt, Iran, Morocco, OPT, and
Pakistan (Table S6).
Proxy Biological Markers of Risk Behavior
There was substantial between-and within-country variation
in HCV prevalence among PWID, with a median of 44% (IQR:
31%–64%) (Table 6). Very high HCV prevalence was reported
such as in Afghanistan (70%, n= 185, Herat), Egypt (63%,
n=100, Alexandria), Iran (over 80%, n=386 prisoners, Tehran),
Libya (94%, n=328, Tripoli), Pakistan (94%, n=161, Karachi),
and Saudi Arabia (75%, n= 1,909, Jeddah) (Table 6).
These figures are consistent with the reported high levels of
sharing of injection equipment, such as in Iran, Pakistan, and
Libya (Table S5).
Available data on the prevalence of syphilis among PWID in
Egypt, Iran, Afghanistan, and Pakistan indicate relatively high
prevalence up to 3%, 8%, 17%, and 18%, respectively (Table S6).
Considerable herpes simplex virus type 2 prevalence has been
reported among PWID in Afghanistan (4%–21%) and Pakistan
(6%–19%) (Table S6). Data on the prevalence of gonorrhoea (0%–
1.8%) and chlamydia (0%–0.7%) were available only in Pakistan
(Table S6).
Knowledge of HIV/AIDS
Levels of basic HIV/AIDS knowledge among PWID in
MENA were high overall, with a median of 93% having ever
heard of HIV/AIDS (IQR: 72%–99%). Still, there was much
variation in the proportion of PWID who correctly identified
reuse of non-sterile needles/syringes and unprotected sex as
modes of HIV transmission (Table S7). Only a median of 45%
(IQR: 30%–63%) of PWID perceived themselves at risk of
HIV/AIDS (Table S7). With a few exceptions of high levels of
HIV testing such as in Lebanon and Oman, the median
prevalence of lifetime testing among PWID ranged between 8%
(Egypt) and 45% (Iran) (Table S7).
Discussion
Injecting Drug Use in MENA
We estimate that there are 626,000 PWID in the MENA region.
Overall, the mean prevalence of injecting drug use (0.24%) is
comparable with global figures which range from 0.06% in South
Asia to 1.50% in Eastern Europe [31]. Prevalence of injecting drug
use in MENA varied between countries and was higher in the
eastern part of the region. Injecting drug use appears to be heavily
concentrated among men; but female PWID are one of the
hardest-to-reach populations in MENA, thereby limiting our
knowledge of this vulnerable group. From limited available data, it
appears that injecting drug use among females has a strong
Table 4. Contribution of injecting drug use as a mode of HIV transmission to the total HIV/AIDS cases by country as per various
studies/reports and countries’ case notification reports [126,190].
Country 2011 Case Notification Report
a Cumulative Data since the Start of the Epidemic
n N Percent Percent due to PWID (end year)
Afghanistan 52 107 48.6 44.3% (2011)
Bahrain 6 16 37.5 62.8% (2008)
Egypt 80 409 19.6 1.6% (2008)
Iran 948 1,588 59.7 69.4% (2011)
Iraq — — — 0.0% (2009)
Jordan 0 17 0.0 2.4% (2011)
Kuwait 0 25 0.0 2.2% (2008)
Lebanon 1 51 2.0 6.1% (2009)
Morocco 9 750 1.2 2.7% (2011)
Oman 5 140 3.6 4.3% (2011)
OPT 0 6 0.0 2.8% (2011)
Qatar 0 1 0.0 —
Pakistan 50 216 23.1 33.2% (2008)
Saudi Arabia 46 394 11.7 6.4% (2009)
Syria 0 69 0.0 2.4% (2009)
Tunisia 3 73 4.1 24.4% (2009)
UAE 1 57 1.8 3.6% (2011)
Yemen 1 236 0.4 1.4% (2009)
Only the most recent available report was used.
aExcept for Bahrain, Egypt, and Iraq (2010 report) and Pakistan (2008 report).
n, number of positive cases that are PWID; N, total number of positive cases; Percent, percent of positive cases that are PWID out of the total number of positive cases;
UAE, United Arab Emirates.
doi:10.1371/journal.pmed.1001663.t004
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association with sex work and having a PWID sexual partner
[78,79].
Emerging HIV Epidemics and HIV Epidemic Potential
among PWID
After synthesizing a large body of data, we documented HIV
epidemics among PWID in one-third of MENA countries. The
HIV epidemic is in a concentrated state in about half the
countries with available data. Iran is the only country with an
established concentrated epidemic, while the most common
pattern is that of emerging concentrated epidemics. Most
observed epidemics in the region are recent, occurring only in
the last decade; around the same time that HIV epidemics
among MSM appear to have emerged (2003) [14]. Of note,
our classification of epidemic states did not depend only on the
size of the epidemic, but also on the trend of HIV prevalence
and other biological data. For example in Pakistan, despite
high HIV prevalence, the epidemic was classified as emerging
since HIV prevalence continues in an increasing trend. HIV
prevalence among PWID in MENA countries with concen-
trated epidemics is overall in the range of 10%–15%, which is
in the intermediate range compared to global figures [31].
However, there are settings with very high prevalence,
most notably in Tripoli, Libya, which appears to have one
of the highest HIV prevalence reported globally (87.1%)
[31,47].
In about 20% of MENA countries, the HIV epidemic among
PWID was low level, with HIV prevalence consistently low for
many years including the most recent IBBSS. In some countries,
such as Jordan, Lebanon, and OPT, no HIV infections were found
in the IBBSS. The available evidence in countries at low level is
restricted to a few cities, and there could be hidden sub-epidemics
in other sites. Nevertheless, the low prevalence could be reflective
of the intrinsic HIV transmission dynamics, levels of risk behavior,
and/or injecting network structure. HIV may not have been
introduced to the PWID community, may have been recently
introduced, or may have been spreading slowly and inefficiently
for some time. The latter may reflect injecting networks with
infrequent and few repeated transmission contacts among PWID
to sustain HIV dynamics. In Lebanon and Syria for example, it
appears that PWID form closed small networks with injecting
occurring in private homes and among friends, and not in large
groups or at shooting galleries [59,80]. The low prevalence could
also be a consequence of stochastic effects where the small number
of individuals who introduced HIV to the PWID population
happened by chance not to have links that could sustain
transmission chains.
Whilst it is conceivable that HIV prevalence may not grow in
countries currently at low level, there are settings where HIV
prevalence increased considerably in a short period of time. For
example in Karachi, Pakistan, after several years of near zero
prevalence [74,75,81,82], HIV prevalence in 2004 increased to
Table 5. Characterization of the state of the HIV epidemic among people who inject drugs in the Middle East and North Africa
based on the HIV biological data and quality and scope of the evidence.
Country Level of HIV Prevalence Trend in HIV Prevalence Geographical Distribution
Quality and Scope of
Evidence
Iran Concentrated Established National Conclusive
Pakistan Concentrated Emerging National Conclusive
Afghanistan Concentrated Emerging At least localized Good
Egypt Concentrated Emerging At least localized Good
Morocco Concentrated Emerging At least localized Good
Libya Concentrated Unknown At least localized Good
Bahrain At least outbreak-type — — Limited
Oman At least outbreak-type — — Poor
Jordan Low-level — — Good
Lebanon Low-level — — Good
OPT Low-level — — Good
Tunisia Low-level — — Good
Syria Low-level — — Limited
Djibouti Unknown — — Poor
Iraq Unknown — — Poor
Kuwait Unknown — — Poor
Saudi Arabia Unknown — — Poor
Sudan Unknown — — Poor
Yemen Unknown — — Poor
Algeria Unknown — — No evidence
Qatar Unknown — — No evidence
Somalia Unknown — — No evidence
UAE Unknown — — No evidence
Countries are sorted by level of HIV prevalence, trend in HIV prevalence, geographical distribution, quality and scope of evidence, then alphabetical order.
UAE, United Arab Emirates.
doi:10.1371/journal.pmed.1001663.t005
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23% in less than 6 months [83], and reached 42% in 2011 [37].
This pattern is not surprising given the reported risky practices and
high HCV prevalence. When HIV prevalence was still very low in
Karachi, HCV prevalence was over 85% [74,75], indicating
substantial use of non-sterile injecting equipment and suggesting
connectivity of injecting networks. In Iran, the substantial HCV
prevalence (up to 80%) was predictive of the explosive HIV
epidemic that occurred subsequently. In both Iran and Pakistan,
injecting networks often seem to be well connected and we found
reports of injecting and sharing occurring among persons who are
Figure 3. Trend of HIV prevalence among male people who inject drugs in (A) Iran and (B) Pakistan. This graph displays all available HIV
prevalence measures for these two countries as extracted from eligible reports (Table 3) and various databases (Table S4). Each dot represents one
HIV prevalence measure for the specific year, and the bars around it define the 95% confidence interval. A pattern of established HIV epidemic is
observed in Iran (A), while a trend of emerging HIV epidemic is observed in Pakistan (B).
doi:10.1371/journal.pmed.1001663.g003
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not necessarily socially related, e.g. in shooting galleries [84,85].
Data on HCV prevalence among PWID in MENA countries with
low-level HIV epidemics are limited. However, HCV prevalence
of 40%–61% among some PWID groups such as in Lebanon,
OPT, and Syria suggest moderate HIV epidemic potential once
the virus is introduced to the PWID community.
Bridging of the HIV Epidemic to Other Population Groups
We found considerable overlap of risk behavior between PWID
and other high-risk groups in MENA; this could play a role in
emerging HIV epidemics, as it creates opportunities for an
infection circulating in one population to be bridged to another
one. In Pakistan, the rapidly growing HIV epidemic among PWID
was followed closely by an emerging epidemic among transgender
sex workers (Figure 4A). Phylogenetic analyses found clustering of
subtypes between the two populations, suggesting that the
infection might have bridged from PWID to the transgender
population [86]. A similar pattern, but in the opposite direction,
may have occurred in Egypt where an emerging epidemic among
MSM [14] preceded the nascent epidemic among PWID
(Figure 4B). While supported by behavioral data [40,42], this
needs to be confirmed by phylogenetic analyses.
Our analysis, focused on the HIV disease burden among PWID,
still masks the role of these epidemics in driving the onward
transmission of HIV to the sexual partners of PWID and further in
the population. The majority of PWID are sexually active and
about half are married. They often engage in risky sexual behavior
as confirmed by the prevalence of STIs. This puts sexual partners
Figure 4. Trend of HIV prevalence among people who inject drugs, and when available men who have sex with men, in repeated
rounds of bio-behavioral surveillance surveys. These graphs display the trend of HIV prevalence in repeated rounds of bio-behavioral
surveillance surveys using state of the art sampling techniques for hard-to-reach populations including respondent driven sampling and time-
location sampling. Country level and aggregate data of multiple cities/provinces are displayed. For consistency between countries and between
different rounds within a given country, unadjusted sample estimates are displayed. Three main patterns of HIV epidemics among PWID are depicted.
A pattern of emerging concentrated epidemics is observed in Pakistan (A) and Egypt (B); a pattern of established concentrated epidemic is observed
in Iran (B); and a pattern of low-level HIV epidemic is observed in Tunisia (D). In Afghanistan (E), there is an emerging epidemic among PWID in
apparently only part of the country; the effect of which was diluted in the second round with the inclusion of new cities with still very limited
prevalence. The potential overlap of the HIV epidemics among PWID and MSM is depicted in Pakistan and Egypt. In Pakistan, an emerging HIV
epidemic among transgender sex workers is observed, but lags the epidemic among PWID (A). In Egypt, the concentrated epidemic among MSM
seems to have preceded the epidemic among PWID (B). In Tunisia, the potential link between the MSM and PWID epidemics is not clear because the
studies were conducted after the epidemics had already risen.
doi:10.1371/journal.pmed.1001663.g004
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of PWID at risk of HIV. A substantial number of infections in
MENA have been documented in women who acquired HIV from
their PWID husbands; and in some countries, the majority of HIV
infections among women were acquired from a PWID sexual
partner [79,87–89]. This highlights the vulnerability of sexual
partners of PWID, who are often female spouses. An illustration of
the role of the HIV epidemics among PWID in driving the onward
transmission of HIV emerges from recent mode of transmission
(MoT) modeling studies in the region [90–92]. For example, in
Iran, PWID directly contributed 56% of the total HIV Incidence;
and indirectly, only through infections to their current sexual
partners, an additional 12% of the total incidence [92]. More
onward HIV transmissions would arise if the sexual partners of
PWID transmitted the infection to their other sexual partners.
Study Limitations
One limitation of our study is that the quantity and quality of
data varied by countries. There were virtually no HIV data in four
countries, and the data quality in six others was insufficient to
assess the status of the epidemic. Longitudinal repeated IBBSS
data were available in only five countries. Six countries have
recently conducted their first round of IBBSS; and in most of
these, subsequent rounds are either planned or being implement-
ed. The quality of data was ‘‘good’’ or ‘‘conclusive’’ in ten out of
the 23 countries.
While most of the data were from cross sectional surveys, there
was a substantial improvement in the quality of data over time.
Many studies were conducted with state of the art research
methodologies in HIV research. These consist of IBBSS studies
using innovative sampling methodologies for hard-to-reach
populations such as respondent-driven sampling and time-location
sampling. Most of these studies benefited from large sample sizes
and some from broad geographical coverage at the national level.
Of note that in several countries there were no recent national
estimates of the number and proportion of PWID. The only
national data available for these countries were extracted from
earlier global reviews of injecting drug use [4,31]. The reviews
were based mainly on estimates by the Reference Group to the
UN on HIV and Injecting Drug Use, which systematically collects
and analyses global data on injecting drug use and HIV [32]. The
Reference Group is considered the main reference for PWID
estimates globally, providing the estimates to the United Nations
Office on Drugs and Crime (UNODC), WHO, and UNAIDS
secretariats. We complemented the Reference Group data with
PWID national risk-group size estimation studies that were
conducted in the last few years in five countries namely
Afghanistan, Iran, Pakistan, Saudi Arabia, and Tunisia. Since
we partly relied on secondary sources of data and since the data
that we used came from studies using different methodologies, our
pooled estimates of the number and prevalence of PWID in
MENA should be considered as approximate figures.
In assessing the status of the epidemic at the country-level, we
did not limit our analysis to one line of evidence, but synthesized
and corroborated findings from different data sources and types
such as HIV prevalence and incidence, notified HIV cases,
injecting and sexual risk behavior, and other related and
contextual data. Thus we could make a comprehensive assessment
of the epidemic status and address potential limitations in any one
line of evidence [93]. We did a rigorous appraisal of the scope and
quality of the evidence within each country by assessing the
amount and geographical coverage of available data, as well as the
ROB and precision of individual point estimates. A qualifier for
the scope and quality of the evidence at the country level was
integrated with each HIV epidemic state assigned. Our search
criteria were expansive, covering different literature sources.
Before the present submitted work, the status of the epidemic
across MENA country was poorly understood. On the basis of our
integrated data synthesis and using rigorous methodology and data
quality assessment, we were able to concretely qualify the epidemic
status in 13 countries (over half of MENA countries), and to
document the overall trend of emerging epidemics. The lack of
evidence in several MENA countries does not preclude the
possibility of hidden epidemics among PWID in these settings.
HIV Response among PWID in MENA
Not only does the region overall lag behind in responding to the
emerging HIV epidemics among PWID; in occasions misguided
policy has contributed to these epidemics. Most notably in Libya,
the large HIV epidemic among PWID appears to have been
exacerbated by restrictions imposed on the sale of needles and
syringes at pharmacies in the late 1990s [11,94]. Overall, harm
reduction programs still remain limited in MENA, and there is a
need to integrate such programs within the socio-cultural
framework of the region [95]. Several countries though have
made significant strides in initiating such programs in recent years
[11,96]. Needle/syringe exchange programs are currently imple-
mented in nine countries, and opioid substitution therapy in five
[96]. Iran remains the leader in the provision of harm reduction
services to PWID with the highest coverage of needle/syringe
exchange programs in the region [12,96]. It appears also to be the
only country in MENA to provide such services in prisons [96,97]
and to provide female-operated harm reduction services targeted
at female drug users [96].
Iran has also initiated triangular clinics that integrate services
for treatment and prevention of injecting drug use, HIV/AIDS,
and other STIs; and these clinics have received international
recognition as best practice [98–100]. Among other interventions
implemented in Iran are drop-in centers, integration of substance
use treatment and HIV prevention into the rural primary health
care system, and community education centers [62,101–105].
These efforts appear to have been successful in reducing sharing of
injecting equipment [106–108], though the coverage of harm
reduction continues to be lower than adequate [104].
Other countries in the region have also made progress in
revising their policies, adopting harm reduction programs, and
integrating such programs in their national strategic plans such as
Afghanistan, Egypt, Lebanon, Morocco, Pakistan, and Tunisia
[11,109]. Access to antiretroviral therapy (ART) has also
expanded in MENA in recent years, and treatment outcomes
reported by country ART programs are comparable to globally
reported outcomes [110,111]. Good adherence to ART has been
also observed, such as in Morocco [112], though some non-
adherence and treatment interruptions, among other obstacles,
have been also reported in several countries [112–114].
Non-governmental organizations (NGOs) have been instrumen-
tal to the success in harm reduction in MENA. It can be noted that
in countries where NGOs are strong, HIV response has been also
strong [11,109]. The Iranian NGO Persepolis, for example, played
an important role in the transformation to effective policies in Iran
[115]. Building on the growing role of NGOs, a regional civil
society network was established in 2007 covering 20 countries in
MENA; the Middle East and North Africa Harm Reduction
Association (MENAHRA) [116]. MENAHRA has the objective of
building the capacity of civil society organizations in harm
reduction efforts through training, sharing of information,
networking and providing direct support to NGOs to initiate or
scale-up harm reduction services. The network is a collaborative
initiative by regional and international organizations with funding
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from international donors, and has been influential in promoting
harm reduction.
Despite the recent progress in harm reduction, HIV prevention
efforts among PWID in MENA remain impeded by generic and
routine planning, competing priorities, limited human capital, and
lack of monitoring and evaluation [7]. National policies remain
inadequate and not sufficiently reflecting evidence-informed
approaches [7]. The scope and coverage of prevention services
remain patchy across and within countries [11,96,109]. An
indicator of the low effective coverage is that only a minority of
PWID report ever being tested, and a smaller proportion report
being tested within the last year [11]. In Morocco and Pakistan,
two countries with a strong HIV response, only 32.5% [117],
47.8% [117], 6.1% [51], and 20.7% [50] of PWID in different
surveys reported ever being tested. Even where services are
available, PWID may not be aware of them, and when aware of
them, they may not utilize them. In Pakistan for example, 37% of
PWID in one study were aware of HIV prevention programs in
their city, but only 19% ever used them [52]. There is an urgent
need to expand the provision, scope, and coverage of HIV
interventions among PWID in MENA to be ahead of the growing
HIV epidemics.
Conclusion
Our study identified a large volume of HIV-related biological
and behavioral data among PWID in the MENA region, including
quality data that appear in the scientific literature for the first time.
The in-depth analyses, the quality assessment of evidence, and the
comprehensive synthesis of data facilitated, for the first time to our
knowledge, a rigorous characterization of the state of the epidemic
among PWID across different countries in this region.
We found robust evidence for HIV epidemics among PWID in
multiple countries, most of which have emerged only recently and
continue to grow. The high risk and vulnerability context suggest
potential for further HIV spread. HIV surveillance among PWID
must be expanded to detect and monitor these budding and
growing HIV epidemics, and to inform effective HIV policy and
programming. This mainly includes conducting IBBSS studies
among PWID in countries where such surveys have not been
conducted yet, and implementing subsequent rounds, for the
provision of longitudinal data, in countries that are already
developing their surveillance base. Population size estimations and
mapping and ethnographic studies are also needed for a better
understanding of the profile and injecting and sexual networks of
PWID in MENA.
The window of opportunity to control the emerging epidemics
should not be missed. HIV prevention among PWID must be
made a priority for HIV/AIDS strategies in MENA; and obstacles
must be addressed for the provision of comprehensive services and
enabling environments for PWID [118]. There is need to review
current HIV programs among PWID in light of the emerging
epidemics, and to develop service delivery models with embedded
links between community-based prevention (needle/syringe ex-
change programs and condom provision), HIV testing, and
treatment (opioid substitution and ART). Such comprehensive
approach has already proven its utility in preventing HIV
transmission among PWID [119–121], but would require better
resource allocation and sufficient services in priority areas for
PWID.
Prevention efforts need to prioritize those most likely to be
reluctant to approach facility-based services, and those with
multiple and overlapping risks. Outreach and peer education can
provide a means to reach those most at risk with information and
services. Access to ART should be expanded in such a region with
one of the lowest ART coverage globally [122]. Such expansion
must address the low diagnosis rate among people living with HIV
[110]. Reaching the at-risk populations even in discreet unpub-
licized ways would contribute positively to HIV prevention
[14,123]. Improving HIV programming among PWID in MENA
is essential not only to confront the growing HIV problem in this
population group, but also to prevent the onward transmission of
HIV, and the bridging of the infection to other groups as has
already occurred in parts of the region.
Supporting Information
Table S1 Precision and risk of bias of individual HIV
prevalence measures among people who inject drugs in
the Middle East and North Africa as extracted from
eligible reports.
(DOCX)
Table S2 Summary of precision and risk of bias of HIV
prevalence measures as extracted from eligible reports.
(DOCX)
Table S3 Subnational estimates of the number and
prevalence of people who inject drugs in the Middle East
and North Africa.
(DOCX)
Table S4 HIV point-prevalence measures among people
who inject drugs as extracted from various databases
including the US Census Bureau database, the WHO/
EMRO testing database, the UNAIDS epidemiological
fact sheets databases, and other sources of data with
unidentified reports.
(DOCX)
Table S5 Measures of injecting risk behavior among
people who inject drugs in the Middle East and North
Africa.
(DOCX)
Table S6 Measures of sexual risk behavior and sexually
transmitted infections prevalence among people who
inject drugs in the Middle East and North Africa.
(DOCX)
Table S7 HIV/AIDS knowledge, perception of risk, and
HIV testing among people who inject drugs in the
Middle East and North Africa.
(DOCX)
Text S1 PRISMA checklist.
(DOCX)
Text S2 Search criteria.
(DOCX)
Text S3 Narrative justification for quality of the
evidence and status of the epidemic at the country level.
(DOCX)
Author Contributions
Conceived and designed the experiments: GRM LJA HAW SLT.
Performed the experiments: GRM SR LJA. Analyzed the data: GRM
LJA HAW. Contributed reagents/materials/analysis tools: HS GR FAA IS
OT DW. Wrote the first draft of the manuscript: GRM. Contributed to the
writing of the manuscript: GRM HAW ST SR HS GR FAA IS OT DW
LJA. ICMJE criteria for authorship read and met: GRM HAW ST SR HS
GR FAA IS OT DW LJA. Agree with manuscript results and conclusions:
GRM HAW ST SR HS GR FAA IS OT DW LJA.
HIV among People Who Inject Drugs in MENA
PLOS Medicine | www.plosmedicine.org 24 June 2014 | Volume 11 | Issue 6 | e1001663
References
1. Obermeyer CM (2006) HIV in the Middle East. BMJ 333: 851–854.
2. UNAIDS (2010) Global Report: UNAIDS report on the global AIDS
epidemic. Available: http://www.unaids.org/documents/20101123_
GlobalReport_em.pdf. Accessed 16 May 2014.
3. Aceijas C, Stimson GV, Hickman M, Rhodes T (2004) Global overview of
injecting drug use and HIV infection among injecting drug users. AIDS 18:
2295–2303.
4. Aceijas C, Friedman SR, Cooper HL, Wiessing L, Stimson GV, et al. (2006)
Estimates of injecting drug users at the national and local level in developing
and transitional countries, and gender and age distribution. Sex Transm Infect
82 Suppl 3: iii10–iii17.
5. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ (2006) Global and
regional burden of disease and risk factors, 2001: systematic analysis of
population health data. Lancet 367: 1747–1757.
6. van Griensven F, de Lind van Wijngaarden JW, Baral S, Grulich A (2009) The
global epidemic of HIV infection among men who have sex with men. Curr
Opin HIV AIDS 4: 300–307.
7. Kilmarx PH (2009) Global epidemiology of HIV. Curr Opin HIV AIDS 4:
240–246.
8. Alkaiyat A, Weiss MG (2013) HIV in the Middle East and North Africa:
priority, culture, and control. Int J Public Health 58: 927–937.
9. Bohannon J (2005) Science in Libya. From pariah to science powerhouse?
Science 308: 182–184.
10. Saba HF, Kouyoumjian SP, Mumtaz GR, Abu-Raddad LJ (2013) Character-
ising the progress in HIV/AIDS research in the Middle East and North Africa.
Sex Transm Infect 89 Suppl 3: iii5–iii9.
11. Abu-Raddad L, Akala FA, Semini I, Riedner G, Wilson D, et al. (2010)
Characterizing the HIV/AIDS epidemic in the Middle East and North
Africa: time for Strategic Action. Middle East and North Africa HIV/AIDS
Epidemiology Synthesis Project. World Bank/UNAIDS/WHO Publication.
Available: http://www-wds.worldbank.org/external/default/WDSContent
Server/WDSP/IB/2010/06/04/000333038_20100604011533/Rendered/
PDF/548890PUB0EPI11C10Dislosed061312010.pdf. Accessed 16 May
2014. Washington (D.C.): The World Bank Press.
12. Abu-Raddad LJ, Hilmi N, Mumtaz G, Benkirane M, Akala FA, et al. (2010)
Epidemiology of HIV infection in theMiddle East and North Africa. AIDS 24 Suppl
2: S5–23.
13. Mumtaz G, Hilmi N, Akala FA, Semini I, Riedner G, et al. (2011) HIV-1
molecular epidemiology evidence and transmission patterns in the Middle East
and North Africa. Sex Transm Infect 87: 101–106.
14. Mumtaz G, Hilmi N, McFarland W, Kaplan RL, Akala FA, et al. (2011) Are
HIV epidemics among men who have sex with men emerging in the Middle
East and North Africa?: a systematic review and data synthesis. PLoS Med 8:
e1000444.
15. Mumtaz GR, Riedner G, Abu-Raddad LJ (2014) The emerging face of the
HIV epidemic in the Middle East and North Africa. Curr Opin HIV AIDS 9:
183–191.
16. UNODC (2011) United Nations Office on Drugs and Crime (2011). World
Drug Report. Available: http://www.unodc.org/documents/data-and-
analysis/WDR2011/World_Drug_Report_2011_ebook.pdf. Accessed 16 May
2014.
17. Beyrer C, Wirtz AL, Baral S, Peryskina A, Sifakis F (2010) Epidemiologic links
between drug use and HIV epidemics: an international perspective. J Acquir
Immune Defic Syndr 55 Suppl 1: S10–S16.
18. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items
for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med
6: e1000097.
19. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The
PRISMA statement for reporting systematic reviews and meta-analyses of
studies that evaluate health care interventions: explanation and elaboration.
PLoS Med 6: e1000100.
20. The Cochrane collaboration (2008) Cochrane handbook for systematic reviews
of interventions. Higgins JPT, Green S, editors. Hoboken (New Jersey): Wiley-
Blackweill.
21. World Health Organization African Index Medicus (AIM). Available: http://
indexmedicus.afro.who.int/. Accessed 16 May 2014.
22. World Health Organization Index Medicus for the Eastern Mediterranean
Region (IMEMR). Available: http://www.emro.who.int/lin/imemr.htm. Ac-
cessed 16 May 2014.
23. International AIDS Society International AIDSConference Abstracts. Available:
http://www.iasociety.org/Default.aspx?pageId= 7. Accessed 16 May 2014.
24. International AIDS Society IAS Conference on HIV Pathogenesis and
Treatment Abstracts. Available: http://www.iasociety.org/Default.
aspx?pageId = 7. Accessed 16 May 2014.
25. International Society for Sexually Transmitted Diseases Research (ISSTDR)
ISSTDR Conference Abstracts. Available: http://www.isstdr.org/previous-
meetings.php. Accessed 16 May 2014.
26. U.S Department of Commerce United States Census Bureau International
Database, Washington (D.C.). Available: http://www.census.gov/population/
international/data/hiv/interactive/. Accessed 16 May 2014.
27. WHO/EMRO Regional database on HIV testing. Cairo: WHO Regional
Office for the Eastern Mediterranean.
28. UNAIDS (2008) UNAIDS/WHO/UNICEF Epidemiological Fact Sheets
database on HIV and AIDS. Geneva: UNAIDS.
29. Vickerman P, Martin NK, Hickman M (2012) Understanding the trends in
HIV and hepatitis C prevalence amongst injecting drug users in different
settings–implications for intervention impact. Drug Alcohol Depend 123: 122–
131.
30. Vickerman P, Hickman M, May M, Kretzschmar M, Wiessing L (2010) Can
hepatitis C virus prevalence be used as a measure of injection-related human
immunodeficiency virus risk in populations of injecting drug users? An
ecological analysis. Addiction 105: 311–318.
31. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, et al. (2008)
Global epidemiology of injecting drug use and HIV among people who inject
drugs: a systematic review. Lancet 372: 1733–1745.
32. IDU Reference Group, The reference group to the UN on HIV and Injecting
Drug Use. Available: https://ndarc.med.unsw.edu.au/project/injecting-drug-
users-reference-group-reference-group-un-hiv-and-injecting-drug-use. Ac-
cessed 16 May 2014.
33. United Nations Population Division. World Population Prospects: the 2010
Revision Population Database. Available: http://esa.un.org/unpd/wpp/index.
htm. Accessed 16 May 2014.
34. UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
(2011) Guidelines on surveillance among populations most at risk for HIV.
Geneva: WHO Press. Available: http://www.unaids.org/en/media/unaids/
contentassets/documents/epidemiology/2011/20110518_Surveillance_
among_most_at_risk.pdf. Accessed 16 May 2014.
35. Wilson D, Halperin DT (2008) ‘‘Know your epidemic, know your response’’: a
useful approach, if we get it right. Lancet 372: 423–426.
36. UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
(2011) Guidelines for second generation HIV surveillance: an update: know
your epidemic. Geneva: WHO Press. Available: http://apps.who.int/iris/
bitstream/10665/85511/1/9789241505826_eng.pdf. Accessed 16 May 2014.
37. Pakistan National AIDS Control Program (2011) HIV second generation
surveillance In Pakistan. National report round IV. Canada-Pakistan HIV/AIDS
Surveillance Project. National Aids Control Program, Ministry Of Health, Pakistan.
Available: http://www.nacp.gov.pk/library/reports/Surveillance%20&%20
Research/HIV-AIDS%20Surveillance%20Project-HASP/HIV%20Second%20
Generation%20Surveillance%20in%20Pakistan%20-%20National%20
report%20Round%20IV%202011.pdf. Accessed 16 May 2014.
38. Afghanistan National AIDS Control Program (2010) Integrated Behavioral &
Biological Surveillance (IBBS) in Afghanistan: year 1 report. HIV Surveillance
Project - Johns Hopkins University School of Public Health, National AIDS
Control Program, Ministry of Public Health. Kabul, Afghanistan.
39. Afghanistan National AIDS Control Program (2012) Integrated Behavioral &
Biological Surveillance (IBBS) in selected cities of Afghanistan: findings of 2012
IBBS survey and comparison to 2009 IBBS survey. Johns Hopkins University
School of Public Health, National AIDS Control Program, Ministry of Public
Health. Kabul, Afghanistan.
40. Family Health International and Ministry of Health Egypt (2006) HIV/AIDS
Biological & Behavioral Surveillance Survey: round one summary report,
Cairo, Egypt 2006. FHI in collaboration with the Ministry of Health and
support from USAID – IMPACT project. Available: http://www.fhi360.org/
sites/default/files/media/documents/EgyptBioBSSsummaryreport2006.pdf.
Accessed 16 May 2014.
41. Soliman C, Rahman IA, Shawky S, Bahaa T, Elkamhawi S, et al. (2010) HIV
prevalence and risk behaviors of male injection drug users in Cairo, Egypt.
AIDS 24 Suppl 2: S33–38.
42. Family Health International and Ministry of Health Egypt (2010) HIV/AIDS
Biological & Behavioral Surveillance Survey: Round Two Summary Report,
Cairo, Egypt 2010. FHI in collaboration with the Ministry of Health and
support from the Global Fund. Available: http://www.fhi360.org/sites/
default/files/media/documents/BBSS%202010_0.pdf. Accessed 16 May
2014.
43. Iran Ministry of Health and Medical Education, Kyoto University School of
Public Health (Japan) (2008) Integrated bio-behavioral surveillance for HIV
infection among injecting drug users in Iran. Draft of the 1st analysis on the
collected data. Tehran: Iran Ministry of Health and Medical Education.
44. Iran Ministry of Public Health (2010) HIV bio-behavioral surveillance survey
among injecting drug users in the Islamic Repubic of Iran. Final report
[Persian], Tehran: Iran Ministry of Public Health.
45. Jordan National AIDS Program (2010) Preliminary analysis of Jordan IBBSS
among injecting drug users. Amman: Ministry of Health.
46. Mahfoud Z, Afifi R, Ramia S, El Khoury D, Kassak K, et al. (2010) HIV/
AIDS among female sex workers, injecting drug users and men who have sex
with men in Lebanon: results of the first biobehavioral surveys. AIDS 24 Suppl
2: S45–S54.
47. Mirzoyan L, Berendes S, Jeffery C, Thomson J, Ben Othman H, et al. (2013)
New evidence on the HIV epidemic in Libya: why countries must implement
HIV among People Who Inject Drugs in MENA
PLOS Medicine | www.plosmedicine.org 25 June 2014 | Volume 11 | Issue 6 | e1001663
prevention programs among people who inject drugs. J Acquir Immune Defic
Syndr 62: 577–583.
48. Kingdom of Morocco Ministry of Public Health (2012) Country Report on
UNGASS Declaration of Commitment. Rabat: Kingdom of Morocco Ministry
of Public Health
49. Palestine Ministry of Health (2011) HIV bio-behavioral survey among injecting
drug users in the East Jerusalem Governorate, 2010. Ramallah: Palestine
Ministry of Health.
50. Pakistan National AIDS Control Program (2008) HIV second generation
surveillance in Pakistan. National Report Round III. Canada-Pakistan HIV/AIDS
Surveillance Project. National Aids Control Program, Ministry Of Health, Pakistan.
Available: http://www.nacp.gov.pk/library/reports/Surveillance%20&%20
R e s e a r c h /H IV - A ID S%2 0 S u r v e i l l a n c e%2 0 P r o j e c t - HAS P /
HIV%20Second%20Generation%20Surveillance%20in%20Pakistan%20-
%20National%20report%20Round%20III%202008.pdf. Accessed 16May 2014.
51. Pakistan National AIDS Control Program (2006–07) HIV second generation
surveillance in Pakistan. National Report Round II. Canada-Pakistan HIV/AIDS
Surveillance Project. National Aids Control Program, Ministry Of Health, Pakistan.
Available: http://www.nacp.gov.pk/library/reports/Surveillance%20&%20
R e s e a r c h /H IV -A IDS%2 0 S u r v e i l l a n c e%2 0 P r o j e c t - HAS P /
HIV%20Second%20Generation%20Surveillance%20in%20Pakistan%20-
%20Round%202%20Report%202006-07.pdf. Last accessed 16 May 2014.
52. Pakistan National AIDS Control Program (2005) HIV second generation
surveillance in Pakistan. National Report Round I. Canada-Pakistan HIV/AIDS
Surveillance Project. National Aids Control Program, Ministry Of Health, Pakistan.
Available: http://www.nacp.gov.pk/library/reports/Surveillance%20&%20
R e s e a r c h /H IV - A ID S%2 0 S u r v e i l l a n c e%2 0 P r o j e c t - HAS P /
HIV%20Second%20Generation%20Surveillance%20in%20Pakistan%20-
%20Round%201%20Report%20-%202005.pdf. Accessed 16 May 2014.
53. Tunisia Ministry of Health, Tunisian Association for Information and
Orientation on HIV (2013) Enqueˆte se´rocomportementale du VIH et des
he´patites virales C aupre`s des usagers de drogues injectables en Tunisie
[French]. Biobehavioral surveillance of HIV and Hepatitis C among injecting
drug users in Tunisia. Tunis: Tunisia Ministry of Health, Tunisian Association
for Information and Orientation on HIV.
54. Tunisia Ministry of Health (2010) Synthe`se des enqueˆtes de se´ropre´valence
et se´rocomportementales aupre`s de trois populations a` vulne´rables au VIH: Les
usagers de drogues injectables, les hommes ayant des rapports sexuels avec des
hommes et les travailleuses du sexe clandestines en Tunisie [French]. Synthesis
of biobehavioral surveillance among the three populations vulnerable to HIV in
Tunisia: Injecting drug users, men who have sex with men, and female sex
workers. Tunis: Tunisia Ministry of Health.
55. Meysamie A, Sedaghat M, Mahmoodi M, Ghodsi SM, Eftekhar B (2009)
Opium use in a rural area of the Islamic Republic of Iran. Eastern
Mediterranean Health Journal 15: 425–431.
56. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, et al. (2010)
Seroprevalence of hepatitis C virus: the first population-based study from Iran.
Int J Infect Dis 14 Suppl 3: e113–116.
57. Emmanuel F, Blanchard J, Zaheer HA, Reza T, Holte-McKenzie M, et al.
(2010) The HIV/AIDS Surveillance Project mapping approach: an innovative
approach for mapping and size estimation for groups at a higher risk of HIV in
Pakistan. AIDS 24 Suppl 2: S77–84.
58. Oman Ministry of Health (2006) HIV risk among heroin and injecting drug
users in Muscat, Oman. Quantitative survey. Preliminary data. Muscat: Oman
Ministry of Health.
59. Syria Mental Health Directorate, Syria National AIDS Programme (2008)
Assessment of HIV risk and sero-prevalence among drug users in greater
Damascus. Damascus: Syrian Ministry of Health. UNODC. UNAIDS.
60. Al-Haddad MK, Khashaba AS, Baig BZ, Khalfan S (1994) HIV antibodies
among intravenous drug users in Bahrain. J Commun Dis 26: 127–132.
61. Morocco Ministry of Health (February 2010) Situation e´pide´miologique du
VIH/Sida et des IST au Maroc [French]. Epidemiological assessment of HIV/
AIDS and STIs in Morocco. Rabat Morocco Ministry of Health.
62. Mojtahedzadeh V, Razani N, Malekinejad M, Vazirian M, Shoaee S, et al.
(2008) Injection drug use in Rural Iran: integrating HIV prevention into iran’s
rural primary health care system. AIDS Behav 12: S7–S12.
63. Todd C, Nasir A, Stanekzai MR, Rasuli MZ, Fiekert, et al. (2010) Hepatitis C
and HIV incidence among injecting drug users in Kabul, Afghanistan [Abstract
MOPDC101]. In: Proceedings of AIDS 2010 - XVIII International AIDS
Conference; 18–23 July 2010; Vienna, Austria.
64. Hadi DHMH, Shujaat PDMGSH, Waheed PDWuZ, Masood PDMGMA
(2005) Incidence of hepatitis C virus and HIV among injecting drug users in
Northern Pakistan: a prospective cohort study [Abstract MoOa0104]. In
Proceedings: IAS 2005 - The 3rd IAS Conference on HIV Pathogenesis and
Treatment; 24–27 July 2005; Rio de Janeiro, Brazil.
65. Jahani MR, Kheirandish P, Hosseini M, Shirzad H, Seyedalinaghi SA, et al.
(2009) HIV seroconversion among injection drug users in detention, Tehran,
Iran. AIDS 23: 538–540.
66. Nai Zindagi, Punjab Provincial AIDS Control Program (2009) Rapid situation
assessments of HIV prevalence and risk factors among people injecting drugs in
four cities of the Punjab. Punjab: Nai Zindagi, Punjab Provincial AIDS Control
Program
67. Kazerooni PA, Lari MA, Joolaei H, Parsa N (2010) Knowledge and attitude of
male intravenous drug users on HIV/AIDS associated high risk behaviors in
Shiraz Pir-Banon jail, Fars Province, Southern Iran. Iranian Red Crescent
Medical Journal 12: 334–336.
68. Asadi S, Marjani M (2006) Prevalence of intravenous drug use-associated
infections. Iranian Journal of Clinical Infectious Diseases 1: 59–62.
69. Todd CS, Nasir A, Stanekzai MR, Fiekert K, Rasuli MZ, et al. (2011)
Prevalence and correlates of HIV, syphilis, and hepatitis B and C infection and
harm reduction program use among male injecting drug users in Kabul,
Afghanistan: A cross-sectional assessment. Harm Reduct J 8: 22.
70. Kuo I, ul-Hasan S, Galai N, Thomas DL, Zafar T, et al. (2006) High HCV
seroprevalence and HIV drug use risk behaviors among injection drug users in
Pakistan. Harm Reduct J 3: 26.
71. Haque N, Zafar T, Brahmbhatt H, Imam G, ul Hassan S, et al. (2004) High-
risk sexual behaviours among drug users in Pakistan: implications for
prevention of STDs and HIV/AIDS. Int J STD AIDS 15: 601–607.
72. Nai Zindagi, UNODCCP, UNAIDS. (1999) Baseline study of the relationship
between injecting drug use, HIV and Hepatitis C among male injecting drug
users in Lahore. Lahore: Nai Zindagi, UNODCCP, UNAIDS
73. Strathdee SA, Zafar T, Brahmbhatt H, Baksh A, ul Hassan S (2003) Rise in
needle sharing among injection drug users in Pakistan during the Afghanistan
war. Drug Alcohol Depend 71: 17–24.
74. Altaf A, Shah SA, Zaidi NA, Memon A, Nadeem ur R, et al. (2007) High risk
behaviors of injection drug users registered with harm reduction programme in
Karachi, Pakistan. Harm Reduct J 4: 7.
75. Altaf A, Shah SA, Memon A (2003) Follow up study to assess and evaluate
knowledge, attitude and high risk behaviors and prevalence of HIV, HBV,
HCV and Syphilis among IDUS at Burns Road DIC, Karachi. External report
submitted to UNODC. Karachi: Marie Adelaide Habilitation Programme.
76. Todd CS, Nasir A, Raza Stanekzai M, Abed AM, Strathdee SA, et al. (2010)
Prevalence and correlates of syphilis and condom use among male injection
drug users in four Afghan cities. Sex Transm Dis 37: 719–725.
77. Aaraj E Report on the situation analysis on vulnerable groups in Beirut,
Lebanon. Beirut: Lebanon Ministry of Health.
78. Burns K (2007) Women injecting drug users in Morocco: a study of women’s
vulnerability to HIV. Unofficial translation from the original French. GTZ
Morocco.
79. Alipour A, Haghdoost AA, Sajadi L, Zolala F (2013) HIV prevalence and
related risk behaviours among female partners of male injecting drugs users in
Iran: results of a bio-behavioural survey, 2010. Sex Transm Infect 89 Suppl 3:
iii41–iii44.
80. Mishwar IBBS_Lebanon (2008) Mishwar. An integrated bio-behavioral
surveillance study among four vulnerable groups in lebanon: men who have
sex with men; prisoners; commercial sex workers and intravenous drug users.
Mid-term Report. Beirut: Mishwar IBBS_Lebanon.
81. Baqi S, Nabi N, Hasan SN, Khan AJ, Pasha O, et al. (1998) HIV antibody
seroprevalence and associated risk factors in sex workers, drug users, and
prisoners in Sindh, Pakistan. J Acquir Immune Defic Syndr Hum Retrovirol
18: 73–79.
82. Parviz S, Fatmi Z, Altaf A, McCormick JB, Fischer-Hoch S, et al. (2006)
Background demographics and risk behaviors of injecting drug users in
Karachi, Pakistan. Int J Infect Dis 10: 364–371.
83. Bokhari A, Nizamani NM, Jackson DJ, Rehan NE, Rahman M, et al. (2007)
HIV risk in Karachi and Lahore, Pakistan: an emerging epidemic in injecting
and commercial sex networks. Int J STD AIDS 18: 486–492.
84. Razzaghi EM, Movaghar AR, Green TC, Khoshnood K (2006) Profiles of risk:
a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J 3:
12.
85. Emmanuel F, Fatima M (2008) Coverage to curb the emerging HIV epidemic
among injecting drug users in Pakistan: delivering prevention services where
most needed. Int J Drug Policy 19 Suppl 1: S59–S64.
86. Khanani MR, Somani M, Rehmani SS, Veras NM, Salemi M, et al. (2011)
The spread of HIV in Pakistan: bridging of the epidemic between populations.
PLoS ONE 6: e22449.
87. Ramezani A, Mohraz M, Gachkar L (2006) Epidemiologic situation of human
immunodeficiency virus (HIV/AIDS patients) in a private clinic in Tehran,
Iran. Arch Iran Med 9: 315–318.
88. Burrows D, Wodak A, WHO (2005) Harm reduction in Iran. Issues in national
scale-up. Report for World Health Organization. Geneva: WHO.
89. Nai Zindagi, Punjab Provincial AIDS Control Program (2008) The hidden
truth: a study of HIV vulnerability, risk factors and prevalence among men
injecting drugs and their wives. Lahore: Government of Punjab.
90. Mumtaz G, Hilmi N, Zidouh A, El Rhilani H, Alami K, et al. (2010) HIV
modes of transmission analysis in Morocco. Rabat: Kingdom of Morocco
Ministry of Health and National STI/AIDS Programme, Joint United Nations
Programme on HIV/AIDS, and Weill Cornell Medical College - Qatar.
91. Mumtaz GR, Kouyoumjian SP, Hilmi N, Zidouh A, El Rhilani H, et al. (2013)
The distribution of new HIV infections by mode of exposure in Morocco. Sex
Transm Infect 89 Suppl 3: iii49–iii56.
92. Gouws E, Cuchi P, on behalf of the International Collaboration on Estimating
HIV Incidence by Modes of Transmission (inlcluding Laith J. Abu-Raddad and
Ghina R. Mumtaz) (2012) Focusing the HIV response through estimating the
major modes of HIV transmission: a multi-country analysis. Sex Transm Infect
88: i76–i85.
HIV among People Who Inject Drugs in MENA
PLOS Medicine | www.plosmedicine.org 26 June 2014 | Volume 11 | Issue 6 | e1001663
93. Rutherford GW, McFarland W, Spindler H, White K, Patel SV, et al. (2010)
Public health triangulation: approach and application to synthesizing data to
understand national and local HIV epidemics. BMC Public Health 10: 447.
94. Tawilah J, Ball A (2003) WHO/EMRO & WHO/HQ Mission to Libyan Arab
Jamahiriya to Undertake an Initial Assessment of the HIV/AIDS and STI
Situation and National AIDS Programme. Tripoli. 15–19 June 2003.
95. Hasnain M (2005) Cultural approach to HIV/AIDS harm reduction in Muslim
countries. Harm Reduct J 2: 23.
96. Harm Reduction International (2012) The global state of harm reduction 2012:
towards an integrated response. Available: http://www.ihra.net/files/2012/
07/24/GlobalState2012_Web.pdf. Accessed 16 May 2014.
97. Asfhar P, Kasrace F (2005) HIV prevention experiences and programs in
Iranian Prisons [MoPC0057]. In: Proceedings Seventh International Congress
on AIDS in Asia and the Pacific; 1–5 July 2005; Kobe, Japan.
98. WHO Regional Office for the Eastern Mediterranean (2004) Best practice in
HIV/AIDS prevention and care for injecting drug abusers: the triangular clinic
in Kermanshah, Islamic Republic of Iran. Cairo: WHO Regional Office for the
Eastern Mediterranean.
99. Razani N, Mohraz M, Kheirandish P, Malekinejad M, Malekafzali H, et al.
(2007) HIV risk behavior among injection drug users in Tehran, Iran.
Addiction 102: 1472–1482.
100. Nassirimanesh B, Trace M, Roberts M (2005) The rise of harm reduction in
the Islamic Republic of Iran. Briefing Paper Eight, for the Beckley Foundation,
Drug Policy Program. Oxford: The Beckley Foundation.
101. Iran Ministry of Health (2006) Treatment and medical education. Islamic
Republic of Iran HIV/AIDS situation and response analysis. Tehran: Iran
Ministry of Health.
102. Zamani S, Kihara M, Gouya MM, Vazirian M, Nassirimanesh B, et al. (2006)
High prevalence of HIV infection associated with incarceration among
community-based injecting drug users in Tehran, Iran. J Acquir Immune
Defic Syndr 42: 342–346.
103. UNAIDS/WHO (2004) AIDS epidemic update 2004. Geneva: UNAIDS/
WHO.
104. Todd CS, Nassiramanesh B, Stanekzai MR, Kamarulzaman A (2007)
Emerging HIV epidemics in Muslim countries: assessment of different cultural
responses to harm reduction and implications for HIV control. Curr HIV/
AIDS Rep 4: 151–157.
105. Zamani S, Farnia M, Tavakoli S, Gholizadeh M, Nazari M, et al. (2010) A
qualitative inquiry into methadone maintenance treatment for opioid-
dependent prisoners in Tehran, Iran. Int J Drug Policy 21: 167–172.
106. Vazirian M, Nassirimanesh B, Zamani S, Ono-Kihara M, Kihara M, et al.
(2005) Needle and syringe sharing practices of injecting drug users participating
in an outreach HIV prevention program in Tehran, Iran: a cross-sectional
study. Harm Reduct J 2: 19.
107. Zamani S, Vazirian M, Nassirimanesh B, Razzaghi EM, Ono-Kihara M, et al.
(2010) Needle and syringe sharing practices among injecting drug users in
Tehran: a comparison of two neighborhoods, one with and one without a
needle and syringe program. AIDS Behav 14: 885–890.
108. Bolhari J, Alvandi M, Afshar P, Bayanzadeh A, Rezaii M, et al. (2002)
Assessment of drug abuse in Iranian Prisons. New York: United National Drug
Control Programme (UNDCP).
109. Abu-Raddad L, Akala FA, Semini I, Riedner G, Wilson D, et al. (2010) Policy
notes. Characterizing the HIV/AIDS epidemic in the Middle East and North
Africa: time for strategic action. Middle East and North Africa HIV/AIDS
Epidemiology Synthesis Project. World Bank/UNAIDS/WHO Publication.
Washington (D.C.): The World Bank Press.
110. WHO/EMRO (2007) Progress towards Universal Access to HIV prevention,
treatment and care in the health sector: report on an indicator survey for the
year 2007 in the WHO Eastern Mediterranean Region. Geneva: WHO/
EMRO.
111. WHO/EMRO (2008) Progress towards Universal Access to HIV Prevention,
treatment and care in the health sector; report on an indicator survey for the
year 2007 in the WHO Eastern Mediterranean Region. Geneva: WHO/
EMRO.
112. Benjaber K, Rey JL, Himmich H (2005) A study on antiretroviral treatment
compliance in Casablanca (Morocco) [French]. Med Mal Infect 35: 390–395.
113. Al Dhahry SH, Scrimgeour EM, Al Suwaid AR, Al Lawati MR, El Khatim
HS, et al. (2004) Human immunodeficiency virus type 1 infection in Oman:
antiretroviral therapy and frequencies of drug resistance mutations. AIDS Res
Hum Retroviruses 20: 1166–1172.
114. UNAIDS RST MENA(2008) Notes on AIDS in the Middle East and North
Africa. Cairo: UNAIDS RST MENA.
115. Razzaghi E, Nassirimanesh B, Afshar P, Ohiri K, Claeson M, et al. (2006)
HIV/AIDS harm reduction in Iran. Lancet 368: 434–435.
116. Middle East and North Africa Harm Reduction Association (MENAHRA).
Available: http://www.menahra.org/. Accessed 16 May 2014.
117. Morocco Ministry of Health, National Aids Control Program, National
Institute of Hygiene, UNAIDS, Global Fund to Fight AIDS Tuberculosis
and Malaria (2012) HIV integrated behavioral and biological surveillance
surveys-Morocco 2011–2012: injecting drug users in Tanger and Nador,
Morocco. Rabat, Morocco. Rabat: Morocco Ministry of Health, National Aids
Control Program, National Institute of Hygiene, UNAIDS, Global Fund to
Fight AIDS Tuberculosis and Malaria.
118. Collumbien M, Chow J, Qureshi AA, Rabbani A, Hawkes S (2008) Multiple
risks among male and transgender sex workers in Pakistan. J LGBT Health Res
4: 71–79.
119. Des Jarlais DC, Marmor M, Paone D, Titus S, Shi Q, et al. (1996) HIV
incidence among injecting drug users in New York City syringe-exchange
programmes. Lancet 348: 987–991.
120. Metzger DS, Woody GE, McLellan AT, O’Brien CP, Druley P, et al. (1993)
Human immunodeficiency virus seroconversion among intravenous drug users
in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune
Defic Syndr 6: 1049–1056.
121. van Ameijden EJ, Watters JK, van den Hoek JA, Coutinho RA (1995)
Interventions among injecting drug users: do they work? Aids 9 Suppl A: S75–
S84.
122. WHO/UNAIDS/UNICEF (2008) Towards universal access: scaling up
priority HIV/AIDS interventions in the health sector. Progress report 2008.
Geneva: WHO/UNAIDS/UNICEF.
123. Jenkins C, Robalino DA (2003) HIV in the Middle East and North Africa: the
cost of inaction. Orientations in Development Series: Washington (D.C.):
World Bank.
124. Afghanistan Ministry of Public Health, Director General of Preventive
Medicine and Primary Health Care, Communicable Disease Directorate
(CDC) (2012) Islamic Republic of Afghanistan. Country report on UNGASS
Declaration of Commitment. Kabul: Afghanistan Ministry of Public Health,
Director General of Preventive Medicine and Primary Health Care,
Communicable Disease Directorate (CDC).
125. UNODC (2010) Afghanistan drug use survey 2009: executive summary. Kabul:
UNODC Afghanistan Office.
126. World Health Organization - Eastern Mediterranean Region (2013) HIV
surveillance systems: regional update 2012. Cairo: WHO Eastern Mediterra-
nean Region.
127. Nasir A, Todd CS, Stanekzai MR, Bautista CT, Botros BA, et al. (2011)
Prevalence of HIV, hepatitis B and hepatitis C and associated risk behaviours
amongst injecting drug users in three Afghan cities. Int J Drug Policy 22: 145–
152.
128. Todd CS, Abed AMS, Strathdee SA, Scott PT, Botros BA, et al. (2007) HIV,
hepatitis C, and hepatitis B infections and associated risk behavior in injection
drug users, Kabul, Afghanistan. Emerging Infectious Diseases 13: 1327–1331.
129. Elghamrawy E, Abaza O, Abou Elmagd S, Ramy H, Atallah S, et al. Risk
behaviours among male injecting drug users in Egypt [Abstract MOPE227
2012]. In Proceedings AIDS 2012 - XIX International AIDS Conference; July
22–27; Washington (D.C.), United States of America.
130. Saleh E, El-Ghazzawi E, El-Sherbini I, Drew W, McFarland W, et al. (1998)
Sentinel surveillance for HIV and high risk behaviors among injection drug
users in Alexandria, Egypt [Abstract 13124]. In: Proceedings AIDS 1998 - XII
International AIDS Conference; 28 June–3 July 1998; Geneva, Switzerland.
131. Attia, Medhat S (1996) HIV seropositivity and KAP towards AIDS among
drug addicts in Alexandria. Bull High Inst Public Health 26: 1–8.
132. Hasan M, Farag A, Ismail M (1994) AIDS and intravenous drug users in Egypt
[Abstract PC0143]. In: Proceedings AIDS 1994 - X International AIDS
Conference; 1994; Yokohama, Japan.
133. El-Ghazzawi E, Hunsmann G, Schneider J (1987) Low prevalence of
antibodies to HIV-1 and HTLV-I in Alexandria, Egypt. AIDS Forsch 2: 639.
134. Honarvar B, Odoomi N, Moghadami M, Afsar Kazerooni P, Hassanabadi A,
et al. (2013) Blood-borne hepatitis in opiate users in iran: a poor outlook and
urgent need to change nationwide screening policy. PLoS ONE 8: e82230.
135. Mehrjerdi ZA, Abarashi Z, Noroozi A, Arshad L, Zarghami M (2013)
Correlates of shared methamphetamine injection among methamphetamine-
injecting treatment seekers: the first report from Iran. Int J STD AIDS.
136. Ilami O, Sarkari B, Khosravani A, Akbartabar Tori M, Hosseini Z (2012) HIV
Seroprevalence among high-risk groups in Kohgiloyeh and Boyerahmad
Province, southwest of Iran, a behavioral surveillance survey. AIDS Behav 16:
86–90.
137. Hashemipour M, Nokhodian Z, Yaran M, Ataei B, Tayeri K, et al. (2013)
Prevalence of HIV infection in individuals with history of intravenous drug use
via community announcement in Isfahan-Iran. Pakistan Journal of Medical
Sciences 29: 395–398.
138. Dibaj R, Ataei B, Yaran M, Nokhodian Z, Tayeri K, et al. (2013) Prevalence of
HIV infection in inmates with history of injection drug use and evaluation of
risk factors, in Isfahan, Iran. Pakistan Journal of Medical Sciences 29: 399–402.
139. Javadi A, Ataei B, Yaran M, Nokhodian Z, Kassaian N, et al. (2013) Prevalence
of HIV infection and related risk factors in Isfahan Drop in Centers. Pakistan
Journal of Medical Sciences 29: 346–350.
140. Eskandarieh S, Nikfarjam A, Tarjoman T, Nasehi A, Jafari F, et al. (2013)
Descriptive aspects of injection drug users in Iran’s national harm reduction
program by methadone maintenance treatment. Iran J Public Health 42: 588–
593.
141. Zamani S, Radfar R, Nematollahi P, Fadaie R, Meshkati M, et al. (2010)
Prevalence of HIV/HCV/HBV infections and drug-related risk behaviours
amongst IDUs recruited through peer-driven sampling in Iran. Int J Drug
Policy 21: 493–500.
142. Ghasemian R, Najafi N, Amirkhanloo K (2011) The study of infections due to
injection drug abuse in the injecting drug users hospitalized at Imam Khomeini
Hospital in Sari and Razi Hospital in Ghaemshahr in 2007–2009. Journal of
Mazandaran University of Medical Sciences 21: 8–15.
HIV among People Who Inject Drugs in MENA
PLOS Medicine | www.plosmedicine.org 27 June 2014 | Volume 11 | Issue 6 | e1001663
143. Zadeh AOT, SeyedAlinaghi S, Hassanzad FF, Hajizadeh M, Mohamadi S,
et al. (2014) Prevalence of HIV infection and the correlates among homeless in
Tehran, Iran. Asian Pacific Journal of Tropical Biomedicine 4: 65–68.
144. Alinaghi SAS, Zadeh AOT, Zaresefat H, Hajizadeh M, Mohamadi SN, et al.
(2013) Prevalence of HIV infection and the correlates among beggars in
Tehran, Iran. Asian Pacific Journal of Tropical Disease 3: 76–78.
145. Aminzadeh Z (2007) Seroepidemiology of HIV, syphilis, hepatitis B and C in
intravenous drug users at Loghman Hakim hospital]. Iran J Med Meicrobiol 1:
53–56.
146. Rahimi-Movaghar A, Razaghi EM, Sahimi-Izadian E, Amin-Esmaeili M
(2010) HIV, hepatitis C virus, and hepatitis B virus co-infections among
injecting drug users in Tehran, Iran. Int J Infect Dis 14: e28–33.
147. Kheirandish P, Seyedalinaghi SA, Hosseini M, Jahani MR, Shirzad H, et al.
(2010) Prevalence and correlates of HIV infection among male injection drug
users in detention in Tehran, Iran. J Acquir Immune Defic Syndr 53: 273–275.
148. Malekinejad M, Mohraz M, Razani N, Khairandish P, McFarland W, et al.
(2008) HIV and related risk behaviors of injecting drug users (IDU) in Iran:
findings from the first respondent-driven sampling (RDS) survey of IDU in
Tehran in 2006–2007 [Abstract THAC0202] 2008; Mexico.
149. Alavi SM, Nadimi M, Shokri S, Zamani G (2012) Seroepidemiology of human
immunodeficiency virus in Illicit substance users in Ahvaz, Iran: 2005–2006.
Jundishapur Journal of Microbiology 5: 474–478.
150. Ghanbarzadeh N, Nadjafi Semnani M (2006) A study of HIV and other
sexually transmitted infections among female prisoners in Birjand [Persian].
Journal of Birjand University of Medical Sciences 13: 69–75.
151. Tofigi H, Ghorbani M, Akhlaghi M, Yaghmaei A, Mostafazadeh B, et al.
(2011) Incidence of hepatitis B and HIV virus at cadaver of IV drug abusers in
Tehran. Acta Med Iran 49: 59–63.
152. Imani R, Karimi A, Rouzbahani R, Rouzbahani A (2008) Seroprevalence of
HBV, HCV and HIV infection among intravenous drug users in Shahr-e-
Kord, Islamic Republic of Iran. East Mediterr Health J 14: 1136–1141.
153. Shamaei M, Marjani M, Baghaei P, Chitsaz E, Rezaei Tabar E, et al. (2009)
Drug abuse profile - patient delay, diagnosis delay and drug resistance pattern -
among addict patients with tuberculosis. Int J STD AIDS 20: 320–323.
154. Pourahmad M, Javady A, Karimi I, Ataei B, Kassaeian N (2007)
Seroprevalence of and risk factors associated with hepatitis B, hepatitis C,
and human immunodeficiency virus among prisoners in Iran. Infect Dis Clin
Prac 15: 368–372.
155. Zamani S, Kihara M, Gouya MM, Vazirian M, Ono-Kihara M, et al. (2005)
Prevalence of and factors associated with HIV-1 infection among drug users
visiting treatment centers in Tehran, Iran. AIDS 19: 709–716.
156. Farhoudi B, Montevalian A, Motamedi M, Khameneh MM, Mohraz M, et al.
(2003) Human immunodeficiency virus and HIV - associated tuberculosis
infection and their risk factors in injecting drug users in prison in Iran. Tehran:
Iran Ministry of Health.
157. Khodadadizadeh A, Esmaeili Nadimi A, Hossieni SH, Shabani Sharbabaki Z
(2006) The prevalence of HIV, HBV and HCV in narcotic addicted persons
referred to the out patient clinic of rafsanjan university of medical sciences in
2003 [Persian]. J Rafsanjan Univ Med Sci 5: 21–30.
158. Alavi SM, Behdad F (2010) Seroprevalence study of hepatitis C and hepatitis B
virus among hospitalized intravenous drug users in Ahvaz, Iran (2002–2006).
Hepat Mon 10: 101–104.
159. Davoodian P, Dadvand H, Mahoori K, Amoozandeh A, Salavati A (2009)
Prevalence of selected sexually and blood-borne infections in Injecting drug
abuser inmates of bandar abbas and roodan correction facilities, Iran, 2002.
Braz J Infect Dis 13: 356–358.
160. Behnaz K, Abdollah A, Fateme F, Mohammadreza R (2007) Prevalence and
risk factors of HIV, hepatitis B virus and hepatitis C virus infections in drug
addicts among Gorgan prisoners. Journal of Medical Sciences 7: 252–254.
161. Alizadeh AH, Alavian SM, Jafari K, Yazdi N (2005) Prevalence of hepatitis C
virus infection and its related risk factors in drug abuser prisoners in Hamedan–
Iran. World J Gastroenterol 11: 4085–4089.
162. Mir-Nasseri MM, Mohammadkhani A, Tavakkoli H, Ansari E, Poustchi H
(2011) Incarceration is a major risk factor for blood-borne infection among
intravenous drug users. Hepat Mon 11: 19–22.
163. Sharif M, Sherif A, Sayyah M (2009) Frequency of HBV, HCV and HIV
infections among hospitalized injecting drug users in Kashan. Indian J Sex
Transm Dis 30: 28–30.
164. Alavi SM, Alavi L (2009) Seroprevalence study of HCV among hospitalized
intravenous drug users in Ahvaz, Iran (2001–2006). J Infect Public Health 2:
47–51.
165. Alavi SM, Etemadi A (2007) HIV/HBV, HIV/HCV and HIV/HTLV-1 co
infection among injecting drug user patients hospitalized at the infectious
disease ward of a training hospital in Iran. Pakistan Journal of Medical Sciences
23: 510–513.
166. Rahbar AR, Rooholamini S, Khoshnood K (2004) Prevalence of HIV infection
and other blood-borne infections in incarcerated and non-incarcerated
injection drug users (IDUs) in Mashhad, Iran. International Journal of Drug
Policy 15: 151–155.
167. Sharifi-Mood B, Metanat M (2006) Infection among hospitalized injection drug
users. Journal of Medical Sciences 6: 686–689.
168. Mirahmadizadeh A, Kadivar M, Hemmati A, Javadi A (2004) Infection with
HIV and hepatitis C and B viruses among injecting drug users in Shiraz,
Southern Iran [Abstract WePeC5981]. In: Proceedings AIDS 2004 - XV
International AIDS Conference; 11–16 July 2004; Bangkok, Thailand.
169. Nowroozi A, Zali M, Gooya M, Kowsarian P, Raoufi M (1998) The
simultanity of HIV, and HBV, HCV and syphilis among the addicted prisoners
[Abstract 60835]. AIDS 1998 - XII International AIDS Conference; 28 June–3
July 1998; Geneva, Switzerland.
170. Alavian SM, Mirahmadizadeh A, Javanbakht M, Keshtkaran A, Heidari A,
et al. (2013) Effectiveness of methadone maintenance treatment in prevention
of hepatitis C virus transmission among injecting drug users. Hepat Mon 13: 9.
171. Azarkar Z, Sharifzadeh G (2010) Evaluation of the prevalence of Hepatitis B,
Hepatitis C, and HIV in inmates with drug-related convictions in Birjand, Iran
in 2008. Hepat Mon 10: 26–30.
172. Mirahmadizadeh AR, Majdzadeh R, Mohammad K, MH F (2009) Prevalence
of HIV and hepatitis C virus infections and related behavioral determinants
among injecting drug users of drop-in centers in Iran. Iranian Red Crescent
Medical Journal 11: 325–329.
173. Amini S, Mahmoodabadi SA, Lamian S, Joulaie M, Farahani MM (2005)
Prevalence of hepatitis G virus (HGV) in high-risk groups and blood donors in
Tehran, Iran. Iranian Journal of Public Health 34: 41–46.
174. Alaei K, Alaei A, Mansoori D, Tabar, Heravi, et al. (2002) The epidemiological
status of IDU and HIV infection in addict cases submitted to HIV/STI/IDU
Counseling and Care Center in Kermanshah province [Abstract LbPp2211].
In: Proceedings: AIDS 2002 - XIV International AIDS Conference; 7–12 July
2002; Barcelona, Spain.
175. Ramia S, Klayme S, Naman R (2003) Infection with hepatitis B and C viruses
and human retroviruses (HTLV-I and HIV) among high-risk Lebanese
patients. Ann Trop Med Parasitol 97: 187–192.
176. Elharti E (2002) HIV epidemiology in Morocco: a nine-year survey (1991–
1999). ElHarti E, personal communication, updated data up to 2008.
International journal of STD and AIDS 13: 839–842.
177. Stulhofer A, Chetty A, Rabie RA, Jwehan I, Ramlawi A (2012) The prevalence
of HIV, HBV, HCV, and HIV-related risk-taking behaviors among Palestinian
injecting drug users in the East Jerusalem Governorate. J Urban Health 89:
671–676.
178. Platt L, Vickerman P, Collumbien M, Hasan S, Lalji N, et al. (2009) Prevalence
of HIV, HCV and sexually transmitted infections among injecting drug users in
Rawalpindi and Abbottabad, Pakistan: evidence for an emerging injection-
related HIV epidemic. Sex Transm Infect 85 Suppl 2: ii17–22.
179. Rahman K, Akhtar A, Aslam M (2006) Seroprevalence of HIV, HBV & HCV
in drug users in Pakistan [Abstract CDC0097]. In: Proceedings AIDS 2006 -
XVI International AIDS Conference; 13–18 August 2006; Toronto, Canada.
180. Nai Zindagi, Punjab Provincial AIDS Control Program (2005) The lethal
overdose: injecting drug use and HIV/AIDS. Lahore: Government of Punjab.
181. Achakzai M, Kassi M, Kasi PM (2007) Seroprevalences and co-infections of
HIV, hepatitis C virus and hepatitis B virus in injecting drug users in Quetta,
Pakistan. Trop Doct 37: 43–45.
182. Bokhari A, Emmanuel F, Abbas S (2006) Integrated biological & behavioral
surveillance: results of pilot studies in Pakistan [Abstract MOPE0552]. In:
Proceedings AIDS 2006 - XVI International AIDS Conference; 13–18 August
2006; Toronto, Canada.
183. Abbasi B, Somroo F (2005) HIV outbreak among injecting drug users in
larkana, pakistan a serious threat for generalized epidemic [Abstract
WeOa0305} IAS 2005 - The 3rd IAS Conference on HIV Pathogenesis and
Treatment; 24–27 July 2005; Rio de Janeiro, Brazil.
184. Abbasi S, Faqir F, Khan S, Zaidi SK, Ahmed SQ, et al. (2009) A serological
study of hepatitis C and human immunodeficiency virus in a cohort of
intravenous drug users in Quetta, Balochistan. Journal of Postgraduate Medical
Institute 23: 3–6.
185. Shah SA, Altaf A, Mujeeb SA, Memon A (2004) An outbreak of HIV infection
among injection drug users in a small town in Pakistan: potential for national
implications. Int J STD AIDS 15: 209.
186. Akhtar A, Aslam M, Zafar M (2004) Determinants of HIV risky behaviors
among drug users in Faisalabad Pakistan [Abstract C11530]. In: Proceedings
AIDS 2004 - XV International AIDS Conference; 11–16 July 2004; Bangkok,
Thailand.
187. Iqbal J, Rehan N (1996) Sero-prevalence of HIV: six years’ experience at
Shaikh Zayed Hospital, Lahore. J Pak Med Assoc 46: 255–258.
188. Khanani MR, Ansari AS, Khan S, Somani M, Kazmi SU, et al. (2010)
Concentrated epidemics of HIV, HCV, and HBV among Afghan refugees.
J Infection 61: 434–437.
189. UrRehman N (2002) Injecting drug use and HIV/AIDS in pakistan [Abstract
MoPeD3667]. In: Proceedings AIDS 2002 - XIV International AIDS
Conference; 7–12 July 2002; Barcelona, Spain.
190. World Health Organization Database of notified HIV/AIDS cases. Cairo:
Eastern Mediterranean Region Office of the World Health Organization.
191. Mohtasham Amiri Z, Rezvani M, Jafari Shakib R, Jafari Shakib A (2007)
Prevalence of hepatitis C virus infection and risk factors of drug using prisoners
in Guilan province. East Mediterr Health J 13: 250–256.
192. Kheirandish P, SeyedAlinaghi S, Jahani M, Shirzad H, Seyed Ahmadian M,
et al. (2009) Prevalence and correlates of hepatitis C infection among male
injection drug users in detention, Tehran, Iran. J Urban Health 86: 902–908.
193. Keramat F, Eini P, Majzoobi MM (2011) Seroprevalence of HIV, HBV and
HCV in persons referred to hamadan behavioral counseling center, west of
Iran. Iranian Red Crescent Medical Journal 13: 42–46.
HIV among People Who Inject Drugs in MENA
PLOS Medicine | www.plosmedicine.org 28 June 2014 | Volume 11 | Issue 6 | e1001663
194. Vahdani P, Hosseini-Moghaddam SM, Family A, Moheb-Dezfouli R (2009)
Prevalence of HBV, HCV, HIV and syphilis among homeless subjects older
than fifteen years in Tehran. Arch Iran Med 12: 483–487.
195. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, et al. (2007)
Prevalence and correlates of hepatitis C virus infection among injecting drug
users in Tehran. Int J Drug Policy 18: 359–363.
196. Nokhodian Z, Ataei B, Kassaian N, Yaran M, Hassannejad R, et al. (2012)
Seroprevalence and risk factors of hepatitis C virus among juveniles in
correctional center in Isfahan, Iran. International Journal of Preventive
Medicine 3: S113–117.
197. Sayad B, Saeed FS, Keyvani H, Rezali M, Asadi T, et al. (2008)
Seroepidemiology of hepatitis C in Kermanshah (West of Iran, 2006). Hepat
Mon 8: 141–146.
198. Nokhodian Z, Meshkati M, Adibi P, Ataei B, Kassaian N, et al. (2012) Hepatitis
C among intravenous drug users in Isfahan, Iran: A study of seroprevalence
and risk factors. International Journal of Preventive Medicine 3: S131–138.
199. Zali MR, Aghazadeh R, Nowroozi A, Amir-Rasouly H (2001) Anti-HCV
antibody among Iranian IV drug users: is it a serious problem. Arch Iranian
Med 4: 115–119.
200. Ataei B, Babak A, Yaran M, Kassaian N, Nokhodian Z, et al. (2011) Hepatitis
C in intravenous drug users: Seroprevalence and risk factors [Persian]. Journal
of Isfahan Medical School 28: 1–9.
201. Sarkari B, Eilami O, Khosravani A, Akbartabartori M, Tabatabaee M (2011)
High prevalence of hepatitis C infection among high risk groups in Kohgiloyeh
and Boyerahmad Province, Southwest of Iran. International Journal of
Infectious Diseases 15: S82.
202. Kaffashian A, Nokhodian Z, Kassaian N, Babak A, Yaran M, et al. (2011) The
experience of hepatitis C screening among prison inmates with drug injection
history [Persian]. Journal of Isfahan Medical School 28.
203. Kassaian N, Adibi P, Kafashaian A, Yaran M, Nokhodian Z, et al. (2012)
Hepatitis C virus and associated risk factors among prison inmates with history
of drug injection in Isfahan, Iran. International Journal of Preventive Medicine
3.
204. Nobari RF, Meshkati M, Ataei B, Yazdani MR, Heidari K, et al. (2012)
Identification of patients with hepatitis c virus infection in persons with
background of intravenous drug use: the first community announcementbased
study from Iran. International Journal of Preventive Medicine 3.
205. Rehan N, Bokhari A, Nizamani NM, Jackson D, Naqvi HR, et al. (2009)
National study of reproductive tract infections among high risk groups of
Lahore and Karachi. J Coll Physicians Surg Pak 19: 228–231.
206. Ahmed F, Irving WL, Anwar M, Myles P, Neal KR (2011) Prevalence and risk
factors for hepatitis C virus infection in Kech District, Balochistan, Pakistan:
most infections remain unexplained. A cross-sectional study. Epidemiol Infect:
1–8.
207. Butt A, Jafri W, Janjua N, Pasha O (2010) Seroprevalence and risk factors for
hepatitis C infection among male prisoners in Karachi, Pakistan.
Am J Gastroenterol 105: S112.
208. Ur Rehman L, Ullah I, Ali I, Khan IA, Iqbal A, et al. (2011) Active hepatitis C
infection and HCV genotypes prevalent among the IDUs of Khyber
Pakhtunkhwa. Virology Journal 8.
209. Ali I, Siddique L, Rehman LU, Khan NU, Iqbal A, et al. (2011) Prevalence of
HCV among the high risk groups in Khyber Pakhtunkhwa. Virol J 8: 296.
210. Njoh J, Zimmo S (1997) Prevalence of antibodies to hepatitis C virus in drug-
dependent patients in Jeddah, Saudi Arabia. East Afr Med J 74: 89–91.
211. Iqbal N (2000) Substance dependence. A hospital based survey. Saudi Med J
21: 51–57.
212. Alzahrani AJ, Dela Cruz DM, Obeid OE, Bukhari HA, Al-Qahtani AA, et al.
(2009) Molecular detection of hepatitis B, hepatitis C, and torque teno viruses
in drug users in Saudi Arabia. J Med Virol 81: 1343–1347.
213. Othman BM, Monem FS (2002) Prevalence of hepatitis C virus antibodies
among intravenous drug abusers and prostitutes in Damascus, Syria. Saudi
Med J 23: 393–395.
HIV among People Who Inject Drugs in MENA
PLOS Medicine | www.plosmedicine.org 29 June 2014 | Volume 11 | Issue 6 | e1001663
Editors’ Summary
Background. About 35 million people worldwide are
currently infected with HIV, the virus that causes AIDS, and
around 2.3 million people become newly infected every year.
HIV is mainly transmitted through unprotected sex with an
infected partner. However, people who inject drugs (PWID)
have a particularly high risk of HIV infection because blood
transfer through needle and syringe sharing can transmit the
virus. Worldwide, 5%–10% of all HIV-positive people are
PWID but in some regions of the world the fraction of all HIV-
positive people that are PWID is even higher. To meet the
global health challenge of the high HIV prevalence (the
proportion of a population that has a specific disease)
among PWID, the Joint United Nations Programme on HIV/
AIDS (UNAIDS) and other international bodies endorse harm
reduction strategies to prevent risky injection behaviors
among PWID. These strategies include education and the
provision of clean needles, syringes, and opioid substitution
therapy.
Why Was This Study Done? To maximize the effect of
these harm-reduction strategies in specific regions, it is
important to understand the status of the HIV epidemic
among PWID. Although surveillance systems provide the
information on HIV infection needed to track the progress of
HIV epidemics among PWID in many regions, little is known
about the HIV epidemic among PWID in the Middle East and
North Africa (MENA, a geographical region that encompasses
countries that share historical, socio-cultural, linguistic, and
religious characteristics). Several factors contribute to the
likelihood of individuals injecting drugs in MENA. For
example, Afghanistan (a MENA country) produces most of
the world’s supply of heroin, which is largely trafficked
through Iran and Pakistan (also MENA countries). In this
systematic review and data synthesis, the researchers use
predefined criteria to identify all the published and unpub-
lished data on HIV prevalence and incidence (the number of
new cases of a disease in a population in a given time)
among PWID in MENA and combine (synthesize) these data
to assess the status of the HIV epidemic in this key
population for HIV transmission in MENA.
What Did the Researchers Do and Find? The researchers
identified 192 reports that reported the prevalence/inci-
dence of HIV, other sexually transmitted infections and
infection with hepatitis C virus (HCV, another virus transmit-
ted through drug injection) among PWID, the prevalence of
injecting or sexual risk behaviors among PWID, or the
number/proportion of PWID in MENA. From these data, the
researchers estimated that there are about 600,000 PWID in
MENA (a prevalence of 0.24 per 100 adults, which is
comparable with figures from other regions). The data
provided evidence for HIV epidemics among PWID in at least
a third of MENA countries, mainly emerging concentrated
epidemics (epidemics that are still growing but in which HIV
infection and transmission are already considerable). HIV
prevalence among PWID in MENA varied considerably,
reaching an extremely high prevalence of 87.1% in Tripoli,
Libya. The data also revealed a high injecting and sexual risk
environment among PWID in MENA (for example, on
average, about a quarter of PWID shared a needle or syringe
in their most recent injection and only a third reported ever
using condoms) that, together with a high prevalence of
HCV and sexually transmitted infections among PWID,
indicates the potential for more and larger HIV epidemics.
What Do These Findings Mean? These findings indicate
that substantial amounts of HIV-related data have been
collected from PWID in MENA but that the coverage and
quality of these data vary widely between countries. They
provide robust evidence for growing HIV epidemics, most of
which have emerged within the past decade, among PWID in
several MENA countries, but do not preclude the possibility
of hidden epidemics among PWID in additional MENA
countries. Overall, these findings suggest that the HIV
epidemic among PWID in MENA is at a relatively early stage.
This window of opportunity to control the emerging
epidemics should not be missed, warn the researchers. HIV
surveillance among PWID in MENA must be expanded to
detect and monitor emerging and growing HIV epidemics,
they suggest, and to inform effective HIV policy and
programming. Improvements in HIV prevention and treat-
ment among PWID in MENA are essential, they conclude, to
confront the growing HIV problem in this population and, to
prevent the onward transmission of HIV from PWID to other
population groups.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001663.
N A 2010 report produced by the World Bank, UNAIDS, and
WHO provides information on the status of the HIV
epidemic in the Middle East and North Africa; the UNAIDS
Middle East and North Africa Regional Report on AIDS 2011
provides further information
N The 2013 UNAIDS World AIDS Day Report provides up-to-
date information about the AIDS epidemic and efforts to
halt it
N The Middle East and North Africa Harm Reduction
Association (MENAHRA) provides information about
harm reduction efforts, services, and programs in the
Middle East and North Africa; Harm Reduction
International provides information about harm reduc-
tion concepts, strategies, programs, and publications
globally
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N NAM/aidsmap provides basic information about HIV/AIDS,
and summaries of recent research findings on HIV care and
treatment
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including informa-
tion on people who inject drugs and HIV/AIDS and on
harm reduction and HIV prevention (in English and
Spanish)
N The US National Institute on Drug Abuse also provides
information about drug abuse and HIV/AIDS (in English
and Spanish)
N Personal stories about living with HIV/AIDS are available
through Avert, Nam/aidsmap, and Healthtalkonline
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